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Abstract 
Elongation factor 1A-1 (eEF1A-1) was previously identified as a mediator of fatty 
acid-induced cell death (lipotoxicity) downstream of endoplasmic reticulum (ER) stress. 
Furthermore, inhibition of the peptide elongation activity of eEF1A-1 with the cyclic 
depsipeptide didemnin B (DB) diminishes ER stress and lipotoxicity in cultured hepatocytes. 
Since ER stress is involved in nonalcoholic fatty liver disease (NAFLD), it was hypothesized 
that administration of DB to obese mice with NAFLD would reduce hepatic lipotoxicity. 
Treatment with DB for one week improved several parameters associated with hepatic 
lipotoxicity and modestly decreased food intake without evidence of illness. Liver 
triglycerides and protein markers of ER stress, plasma measurements of liver enzymes, 
plasma cholesterol, and glucose homeostasis were all improved.  Of these observations, only 
improved plasma liver enzymes and glucose homeostasis were completely attributed to 
reduced food intake. It was concluded that acute intervention with DB improved hepatic 
lipotoxicity in obese mice with NAFLD.   
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Chapter 1  
1 Introduction  
1.1 Obesity and Metabolic Syndrome 
Over the past several decades, diet-induced obesity has steadily become a major 
health concern in North America (Unger and Scherer, 2010). Obesity is defined as the 
accumulation of excess body fat to such an extent that it may lead to adverse health 
effects (Navaneelan and Janz, 2014). Body mass index (BMI) is a well established 
diagnostic tool used to measure obesity. BMI is calculated by dividing a person’s weight 
in kilograms by their height in metres squared (Despres, 2015). A person with a BMI 
greater than 25 kg/m2 is classified as overweight, whereas a person with a BMI greater 
than 30 kg/m2 is classified as obese (Kramer, 2015). Although the relationship between 
an increase in BMI and adverse health outcomes is well established, the diagnostic test is 
not without its limitations. The assessment of adipose by BMI does not take into 
consideration total body composition, including visceral fat and abdominal obesity. 
Furthermore, although increased BMI is an indicator of health risks associated with 
dysregulated metabolism, not all individuals with increased weight experience metabolic 
complications and are therefore considered metabolically healthy obese (Gustafson et al., 
2015). The consequences of overnutrition and inactivity are numerous. Being overweight 
or obese is associated with increased risk of developing many other conditions including 
dyslipidemia, type II diabetes, hypertension, heart disease, stroke, sleep apnea, 
degenerative joint disease, and cancer, among others (Kramer, 2015). The predominant 
cause of obesity is an imbalance in caloric consumption and energy expenditure. 
According to Statistics Canada, one in four adult Canadians, approximately 6.3 million 
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people, were classified as obese in 2011. Since 2003, there has been a 17.5% increase in 
the number of Canadians classified as obese (Navaneelan and Janz, 2014). 
A subset of risk factors for cardiovascular disease and diabetes, that are 
commonly associated with obesity, have been grouped and described as the metabolic 
syndrome (Alberti et al., 2009). Metabolic syndrome is defined by abdominal obesity 
plus two of the following characteristics: elevated fasting blood glucose (≥5.6 mmol/l), 
elevated plasma triglycerides (≥1.7 mmol/l), elevated blood pressure (≥130/85 mm Hg), 
and decreased high-density lipoprotein (HDL) cholesterol (<1.03 mmol/l) (Simmons et 
al., 2010; Wagh and Stone, 2004). Obesity and metabolic syndrome have reached 
epidemic proportions and continue to increase at an alarming rate. The prevalence of 
these health concerns no longer affects only the Western world and is now a serious 
public health issue for low and middle-income countries (Unger and Scherer, 2010).  
 Obesity and metabolic syndrome are associated with lipid accumulation in non-
adipose tissues. Most cells and tissues have a limited ability to store excess lipid. The 
primary function of adipose and adipocytes is to store excess calories as lipid during a fed 
state, and distribute lipid to non-adipose tissues for energy generation during a fasted 
state (Unger and Scherer, 2010). During times of caloric excess and inactivity, 
subcutaneous adipose tissue will initially accommodate excess lipid through the 
expansion and hypertrophy of adipocytes (Gustafson et al., 2015). However, adipose 
tissue also has a limited storage capacity. If this capacity is exceeded, adipocyte 
dysfunction and uncontrolled lipolysis ensue, resulting in elevated circulating free fatty 
acids. In the liver, chronic exposure to increased circulating free fatty acids, which can 
occur during obesity, leads to hepatic insulin resistance. Under physiological conditions 
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during the fed state, insulin suppresses hepatocyte export of excess lipid as very low-
density lipoprotein (VLDL) (Sparks et al., 2012). Hepatic insulin resistance impairs the 
ability of the liver to downregulate the production of VLDL, leading to the 
overproduction and secretion of VLDL, and resulting in hypertriglyceridemia (Adeli et 
al., 2001). This increase in serum triglycerides and flux of free fatty acids from adipose 
and liver leads to the accumulation of lipid in non-adipose tissues such as the pancreas, 
heart and vasculature, skeletal muscle, and kidney (Brookheart et al., 2009) (Figure 1.1). 
Deposition of lipid in these tissues can result in tissue specific insulin resistance, 
inflammation, and cell dysfunction and death (Unger and Scherer, 2010). This 
accumulation of lipid in non-adipose tissue resulting in the disruption of cellular 
homeostasis and contributing to cell death is termed lipotoxicity (Aon et al., 2014; 
Wende et al., 2012). Thus, chronic exposure of non-adipose tissue to elevated 
concentrations of lipids and the accumulation of excess lipid in these organs causes 
cellular dysfunction, and can lead to the development of disease (Unger and Scherer, 
2010).  
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Figure 1.1 Obesity results in ectopic lipid deposition in a variety of organs and 
tissues.  
A diet high in calories and fat along with an inactive lifestyle leads to elevated circulating 
blood glucose, free fatty acids (FA) and triglycerides (TG).  Chronic exposure to caloric 
overload overwhelms the ability of adipose tissue to expand, resulting in adipose failure. 
This leads to a flux of free fatty acids from adipose tissue into the circulation, and 
eventually lipid accumulation in non-adipose tissues such as the pancreas, skeletal 
muscle, heart and vasculature, and liver (represented by yellow circles). Chronic 
exposure to excess free fatty acids impairs the ability of the liver to downregulate the 
production of VLDL, leading to VLDL overproduction and hypertriglyceridemia. 
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1.2 Nonalcoholic Fatty Liver Disease  
Increased  dietary intake of high calorie and high fat foods, coupled with a 
reduction in physical activity leads to an increase in the circulating levels of free fatty 
acids, and consequently an increase in the storage of triglycerides in non-adipose tissues 
such as the liver (Leamy et al., 2013). Nonalcoholic fatty liver disease (NAFLD) 
represents a spectrum of lipid accumulation in the liver from benign steatosis (fatty 
infiltration of the liver) to nonalcoholic steatohepatitis (NASH) (steatosis accompanied 
by inflammation and hepatocyte necrosis), in the absence of excessive alcohol 
consumption (Bayard et al., 2006). NAFLD is strongly associated with obesity and 
insulin resistance. It is considered the hepatic manifestation of metabolic syndrome and is 
now the most common chronic liver disease, affecting 75-80% of obese patients, or 
approximately 20% of the general population in the Western world (Tuyama and Chang, 
2012). Not all patients diagnosed with hepatic steatosis progress to NASH 
(Neuschwander-Tetri, 2010). However, as a result of the prevalence of obesity, NASH is 
now the third most common indication for liver transplant in the United Sates, and is 
projected to be the leading cause of liver transplant within the next two decades (Wang et 
al., 2014b). NASH is associated with significant hepatocyte lipotoxicity, advanced 
fibrosis and cirrhosis, and can lead to the development of hepatocellular carcinoma and 
end stage liver disease (Tuyama and Chang, 2012). 
The diagnosis and staging of NAFLD is a complex process that often begins when 
laboratory test results show elevated liver enzymes (Tuyama and Chang, 2012). To 
confirm a diagnosis of NAFLD, alcoholic fatty liver disease and viral hepatitis must first 
be excluded. Daily alcohol consumption must be below 20 g per day for women and 30 g 
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per day for men to exclude alcoholic fatty liver disease (Bayard et al., 2006). The main 
histological characteristic of NASH is the displacement of the nucleus to the edge of the 
cell. Hepatocyte ballooning, lobular neutrophilic inflammation and Mallory bodies can 
also be present (Sanyal, 2002). Elevated plasma alanine transaminase (ALT) and 
aspartate transaminase (AST) are non-invasive diagnostic markers of liver function 
(Sanyal, 2002). ALT and AST are enzymes located in hepatocytes that are released into 
the circulation upon liver injury. The ratio of AST/ALT is usually less than 1 but 
increases as the severity of liver damage increases (Bayard et al., 2006). However, the 
reliability of liver enzymes alone as a diagnostic tool for staging NAFLD has been 
debated due to the poor sensitivity and specificity of the test. Many patients with NASH 
have AST and ALT levels that fluctuate within the normal limit (Adams and Feldstein, 
2011). The presence of liver steatosis can be diagnosed by various imaging techniques 
such as ultrasound, computerized tomography (CT) scan, and magnetic resonance 
imaging (MRI). Of these, the least expensive and most commonly used method is 
ultrasound, whereas MRI is the most accurate yet most expensive method (Chalasani et 
al., 2012). Despite the efficacy of these routine imaging techniques in detecting steatosis, 
they are unable to distinguish fatty liver from the early stages of NASH (Adams and 
Feldstein, 2011). Liver biopsy remains the only accurate method to diagnose NASH, 
however, biopsies sample only a very small portion of the liver and carry a risk of 
morbidity and mortality and therefore should be performed with caution in patients who 
would benefit the most from diagnostic guidance (Chalasani et al., 2012).  
The progression of NAFLD, from benign steatosis to NASH, is complex and its 
pathogenesis is not fully understood. However, lipid accumulation in the liver, the 
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primary gross morphological characteristic of NAFLD, can be attributed to insulin 
resistance (Utzschneider and Kahn, 2006). Patients with NAFLD generally exhibit a 
reduction in whole-body insulin sensitivity that is driven by insulin resistance in 
peripheral tissues including skeletal muscle, adipose tissue, and liver  (Trauner et al., 
2010). Insulin resistance is associated with impaired suppression of adipose lipolysis, and 
thus increased supply of free fatty acids to the liver. Furthermore, the compensatory 
hyperinsulinemia that occurs during insulin resistance can lead to an increase in de novo 
lipogenesis through the activation of sterol receptor binding protein 1-c (SREBP-1c), a 
transcription factor that regulates expression of lipogenic genes (Utzschneider and Kahn, 
2006). Hyperinsulinemia can also suppress forkhead box protein FOXA2, which leads to 
a decrease in fatty acid oxidation and further accumulation of lipid in the liver. Insulin 
resistance also leads to a reduction in glucose uptake by adipose tissue and skeletal 
muscle, leading to hyperglycemia (Ahmed et al., 2015). This resulting hyperglycemia can 
activate carbohydrate response element binding protein (ChREBP) in hepatocytes, a 
transcription factor which stimulates lipogenesis even further by regulating the 
conversion of excess glucose to fatty acids (Utzschneider and Kahn, 2006). Thus, insulin 
resistance is thought to be very important for the initiation and progression of NAFLD. 
NAFLD has become a major cause of liver-related morbidity in North America. 
As the prevalence of risk factors such as metabolic syndrome, type 2 diabetes, and 
obesity have increased, the prevalence of NAFLD has also increased (Sanyal, 2002). It is 
not known why some patients with NAFLD progress to NASH and end stage liver 
disease while others remain asymptomatic, with only benign hepatic steatosis for their 
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entire life. This suggests that other factors, including genetic and environmental 
determinants, play a role in the progression of the spectrum of disease.  
1.3 Lipotoxicity in Cultured Hepatocytes 
NAFLD is first characterized by an accumulation of neutral lipid, mostly in the 
form of triglycerides, in hepatocytes. As noted in the previous section, progression of this 
disease is associated with insulin resistance and elevated serum free fatty acids (Nehra et 
al., 2001; Tessari et al., 2009). Fatty acids that contribute to hepatic steatosis originate 
from three main sources. The majority (60%) comes from the release of free fatty acids 
stored in adipose tissue. Fatty acids made in the liver through de novo lipogenesis are the 
next most significant contributing factor, responsible for up to 30% of stored hepatic lipid 
content. Finally, dietary fatty acids contribute approximately 10% of hepatic lipid content 
(Firneisz, 2014; Ibrahim et al., 2011; Musso et al., 2009). Free fatty acids, that originate 
from dietary fat or lipolysis of triglycerides stored in adipose, are carried in the 
circulation bound to albumin (Bradbury, 2006; van der Vusse, 2009). When circulating 
free fatty acid concentrations are high they are taken up by the hepatocyte through flip-
flop or facilitated transport. Fatty acid transport proteins (FATP), in particular FATP5, 
have been implicated in the facilitation of fatty acid uptake at the liver (Musso et al., 
2009). Once transported into the hepatocyte, fatty acids can be converted to triglycerides 
and either stored as lipid droplets in the cytosol or exported in VLDL (Bradbury, 2006; 
Hegele, 2009). Fatty acids can also undergo β-oxidation in the mitochondria (Musso et 
al., 2009; Tessari et al., 2009). When hepatocytes are overwhelmed by excess lipid, in 
particular saturated fatty acids, lipotoxic response pathways are activated leading to 
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oxidative and endoplasmic reticulum (ER) stress, ultimately resulting in cell dysfunction 
and death (Brookheart et al., 2009; Wei et al., 2006). 
1.3.1 Saturated and Unsaturated Fatty Acids 
In vitro models of hepatocyte steatosis have been useful in the study of the 
consequences of lipid accumulation and lipotoxicity in the liver. For these models, 
hepatocyte cell lines or primary hepatocytes are treated with pathophysiological 
concentrations of saturated and unsaturated fatty acids conjugated to bovine serum 
albumin (BSA) (Leamy et al., 2013). Fatty acid treatments can be varied to reflect a 
typical Western diet and the conditions the liver is exposed to during obesity and 
metabolic syndrome (Soriguer et al., 2009).  
Studies in cultured liver cells and in rodent models of NAFLD have demonstrated 
that saturated fatty acids, such as palmitate, the most common saturated fatty acid in 
Western diets, are more harmful to hepatocytes than unsaturated fatty acids, such as 
oleate (Leamy et al., 2013; Listenberger et al., 2003; Wei et al., 2006). Saturated fatty 
acids, in contrast to unsaturated fatty acids, preferentially undergo β-oxidation at the 
mitochondria and produce substrates for the synthesis of ceramide; a lipid second 
messenger involved in apoptosis. β-oxidation of saturated fatty acids can also produce 
reactive oxygen species (ROS) that lead to cellular dysfunction by triggering the unfolded 
protein response (UPR) and ER stress response (Faust and Kovacs, 2014; Wei et al., 
2006). Furthermore, unsaturated fatty acids are readily incorporated into triglycerides 
whereas saturated fatty acids are inefficiently esterified and stored as triglycerides 
(Listenberger et al., 2003). Co-incubation of hepatocytes with both saturated and 
unsaturated fatty acids prevents palmitate toxicity by diverting saturated fatty acids to 
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triglyceride formation (Li et al., 2009; Listenberger et al., 2003). Inhibition of stearoyl-
CoA desaturase-1 (SCD1), the enzyme responsible for converting saturated fatty acids to 
unsaturated fatty acids, sensitizes hepatocytes to saturated fatty acid induced apoptosis 
(Li et al., 2009). Furthermore, scd1  knockout mice fed a methionine and choline 
deficient diet, which induces NAFLD, accumulate less triglyceride in the liver compared 
to wild-type mice but have increased serum free fatty acid levels, liver damage, and 
fibrosis. However, scd1 knockout mice fed a methionine and choline deficient diet 
supplemented with oleate have less severe apoptosis and liver injury (Li et al., 2009). 
Taken together, these studies support the concept that it is saturated, and not unsaturated, 
fatty acids that are primarily responsible for hepatocyte lipotoxicity.  
1.3.2 Endoplasmic Reticulum Stress 
The ER is an organelle essential for many different cellular functions including 
protein synthesis, folding and modification, calcium homeostasis, lipid synthesis, and 
carbohydrate metabolism (Ji and Kaplowitz, 2006). Due to the high anabolic burden at 
the ER during NAFLD, not all synthesized proteins are able to be properly folded and 
processed. This disruption of ER homeostasis by lipid excess, which can also occur 
through other stressors such as oxidative stress and disruption of calcium homeostasis, 
results in the accumulation of unfolded or misfolded proteins in the ER lumen, and leads 
to ER stress (Zhou and Liu, 2014). To restore ER homeostasis, eukaryotic cells have 
developed the unfolded protein response (UPR); a physiological process to ensure proper 
protein folding and efficiently remove misfolded proteins from the ER. Activation of the 
UPR inhibits protein synthesis, increases protein folding, and eliminates unfolded 
proteins through degradation in an effort to reduce the burden at the ER (Zhou and Liu, 
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2014). The UPR is initially protective; however, if the UPR is unable to restore 
homeostasis, the ER stress response is activated in order to initiate cell death pathways 
(De Minicis et al., 2012; van der Kallen et al., 2009).  
The UPR activates intracellular signaling pathways mediated by three ER 
localized protein sensors: inositol-requiring enzyme 1α (IRE1α), activating transcription 
factor 6 (ATF6), and double stranded RNA-dependent like ER kinase (PERK) (Ji and 
Kaplowitz, 2006). These protein sensors span the ER membrane and under physiological 
conditions are bound to the protein folding chaperone glucose-related protein 78 
(GRP78), also known as binding immunoglobulin protein (BiP), in an inactive state 
(Zhou and Liu, 2014). In response to the accumulation of unfolded or misfolded proteins, 
GRP78 dissociates from the protein sensors, resulting in their activation, and binds to its 
unfolded or misfolded protein targets. When GRP78 dissociates from IRE1α, IRE1α is 
autophosphorylated and induces the production of the spliced form of X box binding 
protein 1 (XBP1) which regulates the expression of genes encoding protein folding 
chaperones and factors to help restore ER homeostasis (Ozcan et al., 2004). IRE1α also 
induces the activation of stress kinases such as c-Jun-N-terminal kinase (JNK) that 
promote apoptosis (Ibrahim and Gores, 2012). When GRP78 dissociates from ATF6, 
ATF6 translocates to the Golgi apparatus, where it is cleaved into its active form. The 
active form of ATF6 translocates to the nucleus and acts as a transcription factor to 
promote the expression of UPR target genes such as GRP78, XBP1 and C/EBP-
homologous protein (CHOP) (Ji and Kaplowitz, 2006; Zhou and Liu, 2014). When 
GRP78 dissociates from PERK, PERK phosphorylates eukaryotic translation initiation 
factor 2α (eIF2α) resulting in the inhibition of protein synthesis. However, with sustained 
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ER stress, PERK activity promotes the translation of ATF4, which in turn promotes the 
transcription of genes involved in apoptosis,  such as CHOP (Ji and Kaplowitz, 2006; 
Jiang et al., 2014). The UPR and ER stress response are important cellular mechanisms 
that have been implicated in the hepatocellular response to saturated fatty acid excess. 
Both in vitro (cultured hepatocytes) and in vivo (dietary and genetic) models of NAFLD 
are associated with increased expression of UPR and ER stress markers such as CHOP, 
GRP78, phosphorylated JNK, phosphorylated PERK, and phosphorylated eIF2α (Cao et 
al., 2012; Ibrahim and Gores, 2012; Ozcan et al., 2004; Wei et al., 2006).  
1.3.3 Oxidative Stress and Mitochondrial Dysfunction 
In addition to ER stress, elevated levels of ROS, leading to oxidative stress and 
mitochondrial dysfunction, have been shown to play a role in hepatic cytotoxic cell 
response and NASH progression (Leamy et al., 2013). The elevated levels of ROS 
associated with saturated fatty acid overload in hepatocytes can be attributed to increased 
mitochondrial β-oxidation, increased expression of cytochrome P450 2E1 (CYP2E1) and 
CYP4A; the enzymes responsible for the oxidative metabolism of long chain fatty acids, 
and upregulation of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 
(Koek et al., 2011; Li et al., 2008; Park et al., 2014). The majority of fatty acids are 
metabolized through β-oxidation at the mitochondria. β-oxidation shortens fatty acids 
into acetyl-CoA subunits which either enter into the tricarboxylic acid cycle and are 
further oxidized to water and carbon dioxide or are condensed into ketone bodies and 
serve as energy substrates for other tissues (Musso et al., 2009). When mitochondrial 
oxidative capacity becomes impaired, fatty acids accumulate in the cytosol and alternate 
oxidative pathways in peroxisomes and microsomes are activated, resulting in an increase 
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in ROS (Musso et al., 2009). ROS, such as anion peroxide and hydrogen peroxide 
(H2O2), are a normal byproduct of the mitochondrial respiratory chain and are produced 
at complex I and complex III (Brenner et al., 2013; Koek et al., 2011). Under 
physiological conditions, the cytotoxic effects of ROS are mitigated by antioxidant 
systems and enzymatic scavengers including dismutases, peroxidases, and glutathione, 
among others (Brenner et al., 2013; Brookheart et al., 2009). However, in 
pathophysiological conditions, when ROS levels exceed the buffer capacity of these 
systems, they trigger an inflammatory response that leads to oxidative damage, 
mitochondrial dysfunction and the activation of cell death pathways (Brenner et al., 
2013). Excess ROS cause damage to proteins, DNA, lipids, compromise membrane 
integrity, and trigger the upregulation of pro-inflammatory cytokines such as tumor 
necrosis factor-α (TNFα) (Brookheart et al., 2009; Koek et al., 2011).  
 The underlying mechanism of mitochondrial dysfunction is very complex and the 
molecular mechanisms responsible remain poorly understood. Mitochondrial dysfunction 
is characterized by mitochondrial outer-membrane permeabilization, caspase activation 
and release of cytochrome c into the cytosol (Li et al., 2008). Increased ROS production 
is a consequence of this dysfunction but has also been shown to contribute to dysfunction 
(Litvinova et al., 2015). Lipid peroxidation products and TNFα inhibit the electron 
transport chain, and damage mitochondrial DNA resulting in impaired function and an 
increase in the production of ROS. Mitochondrial dysfunction also results in the 
inhibition of β-oxidation of lipids, leading to the accumulation of excess fatty acids in the 
cytosol, where they can further contribute to hepatic steatosis by being incorporated into 
neutral lipids (Koek et al., 2011).  In liver tissue of patients with NASH, mitochondrial 
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function and mitochondrial respiratory chain activity has been shown to be impaired 
(Agrawal and Duseja, 2012; Litvinova et al., 2015; Perez-Carreras et al., 2003). Along 
with these functional irregularities, mitochondrial structural changes, including 
longitudinal or spherical swelling and the development of intramitochondrial crystals 
consisting of phospholipids, have been observed in patients with steatohepatitis (Caldwell 
et al., 2009; Sanyal et al., 2001). Taken together, there is significant evidence to support 
that the complex relationship between oxidative stress and mitochondrial dysfunction 
plays a key role in the pathogenesis and progression of NAFLD. 
1.3.4 Modes of Cell Death in NAFLD: Necrosis and Apoptosis 
There are several modes of cell death that are involved in hepatocellular 
lipotoxicity and associated with the progression of NAFLD. Necrosis, apoptosis, 
necroptosis, and autophagy have all been shown to occur in hepatocytes. Necrosis is an 
unregulated consequence of cell stress characterized by mitochondrial impairment, a 
decrease in adenosine triphosphate (ATP), and failure of ATP-dependent ion pumps. This 
leads to cellular swelling, mitochondrial swelling, the formation of membrane blebs, and 
ultimately cell rupture and the activation of inflammatory responses (Lemasters et al., 
2009; Luedde et al., 2014). Apoptosis, or programmed cell death, is a highly regulated 
process mediated by aspartate specific proteases known as caspases. It is characterized by 
cell shrinkage, nuclear condensation and fragmentation, and plasma membrane blebbing 
leading to the production of apoptotic bodies (Luedde et al., 2014; Schattenberg et al., 
2006). Due to the engulfment of these apoptotic bodies by macrophages, apoptosis, 
unlike necrosis, does not typically generate an inflammatory response within tissues. 
Apoptosis can be initiated through an intrinsic or extrinsic pathway. In hepatocytes, the 
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intrinsic pathway can be triggered by ER stress, JNK activation, and p53 activation. This 
pathway initiates apoptosis through members of the B-cell lymphoma 2 (BCL2) family 
which regulate mitochondrial outer membrane permeabilization, cytochrome c release, 
and caspase activation (Luedde et al., 2014; Martinou and Youle, 2011).  The extrinsic 
pathway is triggered by cytokines such as members of the TNF ligand superfamily, and 
the downstream activation of caspases (Schattenberg et al., 2006). Caspases cleave 
proteins whose loss of function induces apoptosis. Apoptosis in the liver is mediated by 
both extrinsic and intrinsic pathways as hepatocytes require mitochondrial amplification 
via cytochrome c release mediated activation of caspase 3 for efficient cell death (Luedde 
et al., 2014; Scaffidi et al., 1998). Apoptosis and the controlled elimination of cells is an 
important regulator of liver homeostasis however, this mechanism of hepatocyte cell 
death can become excessive during hepatic steatosis, contributing to the progression of 
NAFLD and NASH. Necroptosis incorporates features of both necrosis and apoptosis and 
is defined as necrotic cell death dependent on receptor interacting protein kinases (RIPK) 
1 and 3 (Linkermann and Green, 2014). The cellular pathways involved in necroptosis 
are not well understood and there is little evidence for its involvement in NAFLD, 
however, it is difficult to differentiate between necrosis and necroptosis in vivo 
(Guicciardi et al., 2013). Necroptosis is believed to act as a backup cell death pathway 
when apoptosis is inhibited. Like necrosis, necroptosis results in cellular swelling, cell 
leakage, and immune responses and is a caspase-independent form of cell death triggered 
by TNFα and other death receptors and toll-like receptors (Kaczmarek et al., 2013; 
Linkermann and Green, 2014; Luedde et al., 2014). A general model of lipotoxic cell 
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death in hepatocytes including the pathways described in this section is shown in Figure 
1.2. 
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Figure 1.2  Pathways involved in hepatocyte lipotoxicity. 
Excess saturated fatty acids, such as palmitate, can overwhelm the ability of a hepatocyte 
to store them as triglycerides (lipid droplets), to catabolise them through β-oxidation in 
the mitochondria, and to export them as triglycerides in lipoproteins. This can result in 
the production of reactive oxygen species (ROS) which can lead to oxidative and ER 
stress. Excess palmitate can also impair the structure and integrity of the ER membrane. 
Oxidative stress and impaired ER structure leads to a release of ER calcium which can 
initiate cell death pathways such as apoptosis and necrosis. 
 
18 
 
1.4 Eukaryotic Elongation Factor 1A-1 (eEF1A-1) 
Eukaryotic elongation factor 1A (eEF1A) was originally identified as a mediator 
of aminoacyl-tRNA (aa-tRNA) recruitment to the ribosome during peptide elongation 
(McKeehan and Hardesty, 1969). eEF1A is now known to be involved in other cellular 
processes such as protein degradation, apoptosis and cytoskeletal organization (Mateyak 
and Kinzy, 2010). Mammals express two different isoforms of eEF1A; eEF1A-1 and 
eEF1A-2, which are approximately 92% identical at the amino acid level. These two 
isoforms are tissue specific and differ in their developmental expression patterns (Kahns 
et al., 1998). eEF1A-1 is expressed ubiquitously in mouse and human tissues, however, 
eEF1A-2 is only expressed in skeletal muscle, heart and brain (Khalyfa et al., 2001). 
eEF1A-1 is the only isoform expressed in liver tissue (Newbery et al., 2007). Both 
isoforms function similarly with regards to their role in peptide elongation (Kahns et al., 
1998). 
1.4.1 eEF1A-1 and Protein Synthesis 
The canonical role of eEF1A-1 is to deliver aa-tRNA to the A site of the ribosome 
during elongation allowing for the formation of peptide bonds and the elongation of the 
polypeptide (Mateyak and Kinzy, 2010). eEF1A-1 mediated binding and recruitment of 
aa-tRNA to the ribosome is guanosine-5-triphosphate (GTP)-dependent. GTP is 
hydrolysed to guanosine diphosphate (GDP) after a correct match between the anticodon 
stem and the messenger ribonucleic acid (mRNA) codon (Perez and Kinzy, 2014). 
Comprising 1-2% of total cellular protein, eEF1A-1 is the second most abundant 
eukaryotic protein, after actin (Ejiri, 2002).  eEF1A-1 consists of three distinct domains 
involved in different aspects of its function. Domain I is the GTP binding domain, 
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domain II is involved in the binding of aa-tRNA and domain III is the actin binding 
domain (Marco et al., 2004; Mateyak and Kinzy, 2010). We, and others, have shown that 
in some cell types, including hepatocytes, skeletal myocytes, enterocytes, and pancreatic 
β-cells, eEF1A-1 is primarily localized to the cytosolic compartment associated with the 
ER, in particular ribosomes (Chen et al., 2010; Didichenko et al., 1991; Hayashi et al., 
1989; Minella et al., 1996; Stoianov, 2013; Stoianov et al., 2015).  
1.4.2 Regulation of the Cytoskeleton by eEF1A-1 
In addition to its role in peptide elongation, eEF1A-1 has been to shown to bind 
and mediate actin cytoskeleton organization (Yang et al., 1990). Genetic screens have 
shown that the specific region of eEF1A-1 actin binding is found in domain III (Gross 
and Kinzy, 2005). In some cell types, greater than 60% of eEF1A-1 is estimated to be 
associated with the actin cytoskeleton (Gross and Kinzy, 2005). Studies have shown that 
eEF1A-1 binds actin, inhibits the rate of actin polymerization and stabilizes actin 
filaments (Liu et al., 2002; Liu et al., 1996; Murray et al., 1996). This regulation of the 
actin cytoskeleton is mediated through globular actin (G-actin) binding and filamentous 
actin (F-actin) bundling activity (Murray et al., 1996). Furthermore, eEF1A-1 has been 
shown to bundle, stabilize and sever microtubules under various conditions (Durso and 
Cyr, 1994; Gross and Kinzy, 2005; Murray et al., 1996; Shiina et al., 1994).  
1.4.3 eEF1A-1 and Cell Death 
Several lines of evidence indicate that eEF1A-1 is involved in mediating 
apoptosis in response to cell stress. eEF1A-1 expression is induced by oxidative and ER 
stress and plays a significant role in mediating apoptosis under both conditions 
(Borradaile et al., 2006a; Chen et al., 2000; Lamberti et al., 2004). Studies in mouse 
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fibroblasts have shown a correlation between eEF1A-1 protein levels and the onset of 
apoptosis during serum induced apoptotic conditions (Duttaroy et al., 1998). In cultured 
cardiomyocytes, protein levels of eEF1A-1 increase under H2O2 induced apoptotic 
conditions (Chen et al., 2000). Furthermore, it has been reported that a decrease in 
eEF1A-1 expression confers resistance to palmitate and H2O2 induced oxidative and ER 
stress in CHO cells, cardiomyocytes and hepatocytes (Borradaile et al., 2006a; Stoianov, 
2013; Stoianov et al., 2015). eEF1A-1 has also recently been implicated in anoikis, which 
is a specific form of apoptosis initiated by a loss of cell anchorage (Itagaki et al., 2012). 
Increased membrane levels of eEF1A-1 appear to increase fibroblast susceptibility to 
anoikis during serum starvation conditions while disrupting this increase using small 
interfering RNA (siRNA) results in cellular resistance to anoikis (Itagaki et al., 2012). 
The pro-apoptotic effects of eEF1A-1 expression may partly depend on its interaction 
with the cytoskeleton (Borradaile et al., 2006a). 
1.4.4 Inhibition of eEF1A-1 Activity with Didemnin B 
The structure of eEF1A-1 has been extensively studied and high resolution crystal 
structures have been created to provide detailed information about the different domains 
of eEF1A-1 (Marco et al., 2004). As mentioned in section 1.4.1, eEF1A-1 has three well 
defined domains, each with a different functional role. Didemnin B, a cyclic depsipeptide 
produced by marine tunicates (sea squirts), specifically binds GTP-bound eEF1A-1, 
between domain I (GTP binding) and domain II (aa-tRNA binding), at the ribosome, and 
inhibits peptidyl-tRNA translocation and peptide elongation (Figure 1.3) (Ahuja et al., 
2000; Lee et al., 2012; Marco et al., 2004; Robert et al., 2009). Didemnin B mediated 
inhibition of protein synthesis is eEF1A-1 dependent and acts by binding eEF1A-1 and  
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Figure 1.3 Binding site of didemnin B in eEF1A-1. 
Schematic representation of the structure of eEF1A-1 (red barrels represent α-helices, 
yellow flat ribbons represent β-strands, blue arrows represent turns). Didemnin B 
specifically binds GTP-bound eEF1A-1 between domain I (GTP binding site) and 
domain II (aa-tRNA binding site), represented by the framed area, independent of domain 
III (Actin binding site). Adapted from Marco et al.(2004). 
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inhibiting its release from the ribosomal A-site (Marco et al., 2004). Didemnin B was the 
first marine organism-derived drug to be clinically tested in humans. Clinical trials 
applied the inhibitory effects of didemnin B on peptide elongation and protein synthesis 
for use as an antitumor and anticancer agent (Potts et al., 2015; Robert et al., 2009; Xu et 
al., 2012). The chemotherapeutic activity of didemnin B was first characterized in 
leukemia and clinical trials have gone on to document responses in a wide array of solid 
tumors, although the mechanism of action of didemnin B is still not completely 
understood. Ultimately, didemnin B failed to demonstrate widespread effective antitumor 
activity in clinical trials, and was associated with significant intestinal toxicity. However, 
a recent report suggests that didemnin B may be effective in a subset of acute 
lymphoblastic leukemia (ALL) based on its ability to inhibit both eEF1A-1 and 
palmitoyl-protein thioesterase 1 (PPT1) activity (Potts et al., 2015).  
Recent work from our lab has determined a role for didemnin B and eEF1A-1 in 
hepatocyte lipotoxicity. We have shown that inhibition of the peptide elongation activity 
of eEF1A-1 with didemnin B, at non-cytotoxic concentrations, reduces palmitate-induced 
cell death in HepG2 cells (a model of human hepatocytes) (Stoianov, 2013; Stoianov et 
al., 2015). When these cells were exposed to high palmitate, eEF1A-1 protein was 
rapidly, though modestly, induced, and partially re-localized from its predominant 
location at the ER to polymerized actin at the cell periphery. This early induction and 
subcellular redistribution of eEF1A-1 coincided with the onset of ER stress, and was later 
followed by cell death which could be partially blocked by incubation with didemnin B. 
These data implicated eEF1A-1 in hepatocyte lipotoxicity (Stoianov, 2013; Stoianov et 
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al., 2015). A general model of the role of eEF1A-1 in the pathways involved in 
hepatocyte lipotoxic cell death is shown in Figure 1.4. 
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Figure 1.4 Working model of the role of eEF1A-1 in the pathways involved in 
hepatocyte lipotoxicity.  
Excess saturated fatty acids, such as palmitate, can overwhelm the ability of a hepatocyte 
to store them as triglycerides (lipid droplets), to catabolise them through β-oxidation in 
the mitochondria, and to export them as triglycerides in lipoproteins. This can result in 
the production of reactive oxygen species (ROS) which can lead to oxidative and ER 
stress. Excess palmitate can also impair the structure and integrity of the ER membrane. 
Oxidative stress and impaired ER structure leads to a release of ER calcium which can 
initiate cell death pathways. Under basal conditions, eEF1A-1 (green circles) is localized 
to the ER. Fatty acid overload, in particular palmitate, results in the mobilization of 
eEF1A-1 from the ER to the actin (red circles) cytoskeleton. eEF1A-1 may mediate 
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changes in the actin cytoskeleton that are necessary for the progression of cell death 
and/or may promote cell death through its protein synthetic activity at the ER. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
26 
 
1.5 Hepatic Lipotoxicity in Mouse Models of Obesity 
Studies of the involvement of hepatic lipotoxicity in NAFLD progression rely on 
suitable rodent models of the disease. There are several mouse models of obesity and 
NAFLD; however, few of these have the complete set of characteristics associated with 
the human disease. Currently, there is no single rodent model that encompasses the full 
spectrum of human disease progression (Imajo et al., 2013). There are two different 
classifications of rodent models of obesity and NAFLD that are readily available. The 
first group includes genetically modified mice in which liver disease and characteristics 
of metabolic syndrome develop spontaneously (Imajo et al., 2013). The second group 
includes models in which disease is induced through dietary intervention (Imajo et al., 
2013). Each model poses a different set of advantages and disadvantages (Anstee and 
Goldin, 2006). 
1.5.1 Genetic Models 
Leptin-deficient, also known as ob/ob, mice on a C57BL/6J background have a 
mutation in the leptin encoding obese (ob) gene on chromosome 6 and therefore lack a 
satiety signal (Anstee and Goldin, 2006). Leptin is a 16 kDa adipokine (Anstee and 
Goldin, 2006). It is an anorexigenic peptide that acts on the hypothalamic ventral median 
nucleus to regulate appetite (Anstee and Goldin, 2006; Kelesidis et al., 2010). The 
secretion of leptin from adipose tissue and its binding to leptin receptors expressed in the 
brain and peripheral tissues signals satiety and reduces caloric intake (Margetic et al., 
2002). Leptin also mitigates excess ectopic accumulation of lipid in non-adipose tissues 
by stimulating fatty acid oxidation (Unger and Scherer, 2010). Ob/ob mice are constantly 
in a state of perceived starvation and if given the opportunity will overeat and become 
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obese (Anstee and Goldin, 2006). This results in a hyperphagic, hyperinsulinemic and 
hyperglycemic phenotype (Nagarajan et al., 2012). Histological characteristics of ob/ob 
mice include hepatic lipid deposition and steatosis, and enlarged pancreatic islets of 
Langerhans (Anstee and Goldin, 2006). The ob/ob model has increased expression of 
TNFα and excess white adipose tissue which promotes adipose tissue lipolysis and the 
subsequent flux of free fatty acids to the liver, contributing to the development of hepatic 
steatosis (Anstee and Goldin, 2006). SREBP-1c is also activated in the livers of ob/ob 
mice leading to increased fatty acid synthase activity and de novo lipogenesis. Ob/ob 
mice develop hepatic steatosis and NAFLD spontaneously; however, unlike humans with 
NAFLD, they do not progress to NASH. This model requires a secondary insult such as 
administration of a methionine and choline deficient diet, or lipopolysaccharide 
endotoxin to trigger progression to steatohepatitis (Nagarajan et al., 2012; Takahashi et 
al., 2012). The ob/ob model is also protected against fibrosis due to defects in 
transforming growth factor (TGF)-β production associated with the C57BL/6J 
background (Anstee and Goldin, 2006). This leads to a reduction in TGFβ-dependent 
genes such as pro-collagen type 1, resulting in the inhibition of fibrosis (Cheng et al., 
2009; Peverill et al., 2014). Resistance to hepatic fibrosis means that ob/ob mice are not 
an accurate model for the study of the end stages of NASH (Basaranoglu and Ormeci, 
2014). A counterpart to the ob/ob mouse is the db/db mouse. Db/db mice, on a C57BL/6J 
background, have a natural mutation in the diabetes (db) gene on chromosome 4 that 
encodes the leptin receptor (Ob-Rb) and results in obesity, dyslipidemia, insulin 
resistance, pancreatic β-cell dysfunction and macrovesicular hepatic steatosis (Anstee and 
Goldin, 2006; Imajo et al., 2013; Wang et al., 2014a). Db/db mice have normal or 
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elevated leptin levels, however; due to the mutation in the leptin receptor they are 
resistant to its effects (Nagarajan et al., 2012). Like the ob/ob mouse model, NAFLD in 
db/db mice will not progress from hepatic steatosis to NASH, unless provided with a 
secondary insult such as administration of a methionine and choline deficient diet 
(Takahashi et al., 2012). Both the ob/ob and db/db mouse models develop obesity, insulin 
resistance and metabolic syndrome quickly. Thus, there is no need for lengthy feeding 
protocols, invasive procedures or surgical interventions (Wang et al., 2014a). They are 
also representative of the human presentation of these metabolic conditions (Takahashi et 
al., 2012), and are useful for studying the progression through the spectrum of hepatic 
lipid accumulation, and the early stages of hepatic lipotoxicity (Anstee and Goldin, 
2006).  
1.5.2 Diet-induced Models 
Diet-induced models of obesity can be time consuming depending on the length 
of the feeding protocol required. However, when compared to genetic models of obesity, 
they are likely more representative of obesity, metabolic syndrome, and the development 
of NAFLD found in the human population. 
High fat diets can be used to induce hepatic steatosis and NASH in rodent models. 
However, using a diet to induce NAFLD can result in inconsistencies in the degree of 
steatosis, inflammation, and fibrosis (Nakamura and Terauchi, 2013). The degree of 
induction of these characteristics of metabolic syndrome depends on the rodent strain, the 
composition of the diet; in particular the fat content, and the duration of the treatment 
(Nakamura and Terauchi, 2013; Takahashi et al., 2012). Choosing the correct rodent 
strain is important, as although the majority of rodents become obese on a high fat diet, 
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there are often discrepancies in weight, glucose intolerance, insulin resistance, and 
dyslipidemia (Fellmann et al., 2013). Long-term exposure to high fat diet has been shown 
to consistently induce obesity, insulin resistance and NASH in C57BL/6J mice but does 
not produce liver fibrosis (Anstee and Goldin, 2006; Hill-Baskin et al., 2009). A typical 
high fat diet consists of a minimum of 60% of calories from fat, an extreme which is not 
represented in the diets of human populations of obesity and therefore lacks clinical 
significance (Ghibaudi et al., 2002; Johnston et al., 2007). A more relevant diet, 
representative of the diet consumed by humans with metabolic syndrome, is the Western 
diet- a high fat, high carbohydrate diet, which consists of approximately 40% of calories 
from fat (Meek et al., 2010). Western diet, which is representative of the diet consumed 
by humans in Westernized countries, induces obesity, insulin resistance and NASH like 
the high fat diet described above. However, as a result of its lower fat percentage, much 
longer feeding protocols are required to induce significant NAFLD progression 
(Basaranoglu et al., 2013; Myles, 2014; Tsuchiya et al., 2012).  
 Carbohydrate adjusted diets can also be used to induce obesity and NAFLD in 
rodents, including C57BL/6J mice (Anstee and Goldin, 2006; Nakamura and Terauchi, 
2013). Changes in diets worldwide have led to an increase in the consumption of 
processed foods rich in both fat and high fructose corn syrup (Kargulewicz et al., 2014). 
Like high fat and Western diets, diets rich in fructose lead to the development of severe 
obesity, hyperinsulinemia, hepatic steatosis and glucose intolerance in mice (Imajo et al., 
2013). High fructose diets have also been found to induce oxidative stress and increase 
expression of proinflammatory cytokines in the liver, but do not lead to fibrosis or 
hepatocellular carcinoma (Imajo et al., 2013). The primary site of fructose metabolism is 
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the liver, however, unlike glucose, uptake and metabolism of fructose is not negatively 
regulated by phosphofructokinase resulting in increased de novo lipogenesis 
(Basaranoglu et al., 2013; Elliott et al., 2002). Furthermore, fructose does not stimulate 
insulin or leptin secretion, and prevents the inhibition of the secretion of ghrelin; an 
orexigenic peptide, leading to impaired satiety signals and resulting in the obesity and 
hepatic steatosis characteristic of high fructose diets (Basaranoglu et al., 2013; Inui, 
2001). 
1.6 Objectives and Hypothesis 
1.6.1 Rationale 
eEF1A-1 was initially identified as a mediator of lipotoxic cell death through a 
genetic screen. This screen used a ROSAβgeo retroviral promoter trap in CHO cells to 
identify factors that, when disrupted, conferred resistance to palmitate-induced cell death 
(Borradaile et al., 2006a). Subsequent studies showed that inhibiting eEF1A-1 expression 
and/or activity, using either siRNA or chemical inhibition with didemnin B conferred 
resistance to palmitate-induced death in cardiomyocytes and in HepG2 cells (Borradaile et 
al., 2006a; Stoianov, 2013; Stoianov et al., 2015). Moreover, in vivo, eEF1A-1 expression is 
induced in the livers of obese mice with severe hepatic steatosis (Stoianov, 2013; Stoianov et 
al., 2015).  
The goal of this thesis was to extend these previous studies in cardiomyocytes and 
hepatocytes to a mouse model of obesity and NAFLD and to further investigate the effects of 
eEF1A-1 inhibition in HepG2 cells.  
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1.6.2 Hypothesis 
Inhibition of eEF1A-1 peptide elongation activity decreases hepatic ER stress and 
lipotoxicity.  
1.6.3 Specific Objectives 
1. Determine the effect of didemnin B on hepatic lipotoxicity in genetically obese mice  
2. Determine the effect of didemnin B on palmitate-induced ER stress and cell death in 
HepG2 cells 
1.6.4 Relevance to Disease 
Metabolic syndrome, obesity, and associated NAFLD are increasing in prevalence 
throughout the world, yet little is known about the mechanism responsible for 
progression of NAFLD. eEF1A-1 has been identified as a mediator of lipotoxic cell death 
in cultured hepatocyte-like cells (Stoianov, 2013; Stoianov et al., 2015). However, 
whether eEF1A-1 plays a significant role in hepatocyte lipotoxic responses in vivo is 
unknown. A greater understanding of the mechanism of action of eEF1A-1 in lipotoxicity 
may provide insight into the progression of this spectrum of liver disease (Figure 1.5).  
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Figure 1.5 Progression of nonalcoholic fatty liver disease. 
Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic 
syndrome and represents a spectrum of lipid accumulation in the liver ranging from 
benign steatosis to nonalcoholic steatohepatitis (NASH). Metabolic syndrome and the 
resulting flux of non-esterified fatty acids (NEFA) from adipose, hypertriglyceridemia, 
and de novo lipogenesis lead to hepatic steatosis. Little is known about the causes of 
progression of NAFLD. It is unknown if eukaryotic elongation factor 1A-1 (eEF1A-1) 
plays a role in the progression of NAFLD to NASH and end stage liver disease. Adapted 
from Tailleux et al. (2012). 
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Chapter 2  
2 Materials and Methods  
2.1 Mice 
Studies were approved by the Western University Animal Care Committee and 
performed in accordance with the Canadian Guide for the Care and Use of Laboratory 
Animals. Five-week old male C57BL/6J and leptin-deficient (ob/ob) mice (Jackson 
Laboratory, Bar Harbor, ME) were fed ad libitum on AIN-76A semi-purified diet (17.7% 
protein, 64.9% carbohydrate, and 5.2% fat by weight) (Harlan Teklad, Indianapolis, IN) 
for 4 weeks. During week 5, mice were given intraperitoneal (i.p.) injections of didemnin 
B (50 µg/kg) or vehicle control on day 1, 4, and 7. Didemnin B was obtained from the 
Open Chemical Repository of the Developmental Therapeutics Program at the National 
Cancer Institute (NIH), and solubilized in 1% dimethyl sulfoxide (DMSO), 5.2% 
PEG400, 5.2% Tween 80, and 88.6% sterile saline (Robert et al., 2009). Body weight and 
food consumption were measured daily and a group of leptin-deficient plus vehicle 
control mice were pair-fed to match leptin-deficient plus didemnin B mice for caloric 
intake (Figure 2.1).  
Prior to sacrifice, glucose tolerance was measured following a 6 h fast and oral 
gavage of a 20% solution of D-glucose (BDH Chemicals, United Kingdom) to deliver a 
dose of 1 g of glucose/kg body weight. Insulin tolerance was measured following a 6 h 
fast and i.p. injection of 0.6 IU of insulin (Novo Nordisk Inc, Denmark) /kg body weight. 
Blood glucose levels were measured using an Ascensia Contour glucometer (Bayer 
Healthcare, Toronto, ON). Animals were sacrificed using carbon dioxide (CO2). Upon 
sacrifice, body weight was recorded, blood was obtained by cardiac puncture, and tissues  
  
Figure 2.1 Animal experimental model schematic.
Five week old male C57BL/6J and 
76A semi-purified diet for 4 weeks. During week 5, 
to either experimental or control groups and given i.p. inj
µg/kg) or vehicle control, while C57BL/6J mice were given i.p. injections of vehicle 
control, on day 28, 31, and 34. Prior to sacrifice on day 38, glucose tolerance and insulin 
tolerance were measured. Upon sacrifice, blood and ti
analyses of gross histological determinations of morphology and lipid content, and for 
biochemical determinations of specific lipid species and specific protein contents. 
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were harvested, weighed and processed for gross histological determinations of 
morphology and lipid content, and for biochemical determinations of specific lipid 
species and specific protein contents. 
2.2 Cell Culture  
HepG2 cells were obtained from the American Type Culture Collection 
(Rockville, MD). HepG2 human hepatoma cells, like normal human and rodent liver, 
exclusively express the eEF1A-1 variant of eEF1A (Grassi et al., 2007; Newbery et al., 
2007). This characteristic is not shared by other, less-differentiated cell lines including 
JHH6, HuH7, and rat McArdle RH-7777 (Grassi et al., 2007). Also, like normal human 
liver, HepG2 cells exclusively secrete full-length apoB100 which responds to 
physiological stimuli such as insulin and oleate. Cells were grown on 100 mm culture 
dishes at 37°C and 5% CO2 and maintained in 10 ml of Eagles minimum essential 
medium (EMEM) (Lonza Biowhittaker, Basel, Switzerland) supplemented with 10% 
fetal bovine serum (FBS), 50 IU/ml penicillin, 50 µg/ml streptomycin, 0.5 µg/ml 
fungizone and 2 mM L-glutamine (Life Technologies, Carlsbad, CA). Cells were split 
(1:6-1:8) every 7 days using trypsin-EDTA. For experiments, cells were plated in 6-well 
(35 mm), or 24-well (15.5 mm) culture plates (Greiner Bio-One, Monroe, NC).  
For fatty acid treatments, media was supplemented with 1.0 mM palmitate. Fatty 
acids were prepared by heating a 20 mM solution of palmitate in 0.02 M NaOH at 70°C 
for 30 minutes. Solubilization of fatty acids was facilitated by adding 1 N NaOH 
dropwise. Fatty acids were complexed to 30% fatty acid free BSA (Sigma-Aldrich, St. 
Louis, MO) at a fatty acid to BSA ratio of 2:1 and then added to cell culture media. BSA-
NaOH supplemented media was used as a control. A 1.0 mM fatty acid concentration was 
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used to reflect the high physiological and pathophysiological conditions tissues are 
exposed to during obesity and metabolic syndrome (Soriguer et al., 2009).  
2.3 Liver Histology  
For analyses of liver tissue morphology and lipid droplet content in C57BL/6J and 
ob/ob mice, liver samples were embedded in optimal cutting temperature compound 
(OCT) (Sakura Finetek USA, Inc, Torrance CA) at the time of sacrifice. Hepatic sections 
(8 µm) were prepared with a cryostat (Leica Biosystems, Germany) and stained with 
either hematoxylin and eosin (H&E) (Leica Biosystems, Germany) or Oil Red O (ORO) 
(Sigma-Aldrich, St. Louis, MO). Sections were imaged using an inverted Olympus BX51 
microscope using 10X, 20X and 40X objectives.  
2.4 Liver Lipids 
Total liver lipids were extracted using the Folch method (Folch et al., 1957), from 
samples frozen in liquid nitrogen and subsequently stored at -80°C. Triglycerides, free 
cholesterol, and total cholesterol from chloroform extracts of liver tissue were determined 
by enzymatic, colorimetric assays using reagents from Roche Diagnostics (Laval, QC) 
for triglyceride assays and reagents from Wako Diagnostics (Richmond, VA) for free 
cholesterol and total cholesterol assays (Assini et al., 2013). All plasma and liver lipid 
measurements were performed through the Metabolic Phenotyping Laboratory in Robarts 
Research Institute.  
2.5 Plasma Insulin, Plasma Lipids, and Plasma Liver Enzymes 
Plasma insulin was measured using ultrasensitive mouse-specific enzyme-linked 
immunosorbent assays (ELISA) (Alpco Diagnostics, Windham, NH) (Assini et al., 2013). 
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Plasma triglyceride, total cholesterol and free fatty acid concentrations from C57BL/6J 
and ob/ob mice were measured via enzymatic, colorimetric assays using reagents 
obtained from Roche Diagnostics (Laval, QC). Plasma AST and ALT, markers of hepatic 
cell injury (Sanyal, 2002), were measured using enzymatic rate assays by the London 
Health Sciences Centre Core Laboratory.  
2.6 Fast Performance Liquid Chromatography Profiles of Plasma 
Lipoproteins 
Plasma lipoprotein distribution in C57BL/6J and ob/ob mice was determined by 
Fast Performance Liquid Chromatography (FPLC) using a modified method previously 
described by Assini et al. (2013). Fresh EDTA plasma (50 µl) was separated by FPLC 
using an AKTA purifier and a Superose 6 column. A constant flow rate of 0.4 ml/minute 
was used to collect 750 µl fractions. A 125 µl aliquot of each fraction was used to 
measure total cholesterol and triglyceride enzymatically in samples on a 96 well 
microtitre plate with 75 µl of two times concentrated reagents (triglyceride, Roche 
Diagnostics, Laval, QC; cholesterol, Wako Diagnostics, Richmond, VA; standards, 
Randox, Crumlin, Co. Antrim, United Kingdom). 
2.7 Immunoblot Analyses 
For analyses of hepatic protein expression in mice, livers were harvested, snap 
frozen in liquid nitrogen, and tissue homogenates were prepared using a WHEATON 
tissue homogenizer (WHEATON, Millville, NJ) and drill  in radioimmunoprecipitation 
assay (RIPA) buffer (150mM NaCl, 1.0% IGEPAL® CA-630, 0.5% sodium 
deoxycholate, 0.1% SDS, and 50 mM Tris-HCl, pH 8.0) containing protease and 
phosphatase inhibitors (protease inhibitors, Roche Diagnostics, Laval, QC; RIPA, 
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phosphatase inhibitors, Sigma-Aldrich, St. Louis, MO). Homogenates were centrifuged 
for 2 minutes at 14,000 rpm to remove insoluble debris. Total protein in the supernatants 
was quantified using the Pierce Bicinchoninic Acid (BCA) Protein Assay Kit (Thermo 
Scientific, Rockford, IL). Aliquots containing 75-100 µg were diluted 1:1 with 2X 
Laemmli sample buffer (LSB) (Bio-Rad, Hercules, CA) and heated to 100ºC for 5 
minutes. Samples were resolved using a Mighty Small II Mini Vertical Electrophoresis 
System (Hoefer Inc., Holliston, MA) and Pierce Precise 10% SDS-polyacrylamide gel 
electrophoresis (PAGE) (Thermo Scientific, Rockford, IL). Samples were then 
transferred to a 0.45 µm Amersham Hybond polyvinyl difluoride (PVDF) membrane (GE 
Healthcare Life Sciences, United Kingdom) using the Panther Semi-Dry Electroblotter 
transfer apparatus (OWL Scientific Inc., Thermo Scientific, Rockford, IL). Membranes 
were incubated in 5% BSA (Millipore, Billerica, MA) in Tris-Buffered Saline, 0.1% 
Tween-20 (Bio-Rad, Hercules, CA) (TBS-T) blocking buffer for 1 h. To detect 
eukaryotic elongation factor 1A-1 (eEF1A-1), membranes were incubated overnight at 
4ºC with a 1:1000 dilution of anti-eEF1A-1 rabbit polyclonal antibody (Cell Signaling 
Technology, Danvers, MA), and then a 1 h incubation with a 1:5000 dilution of a 
horseradish peroxidase (HRP)-conjugated polyclonal anti-rabbit antibody (Santa Cruz 
Biotechnology, Dallas, TX). Phosphorylated eukaryotic translation initiation factor 2α 
(eIF2α)  was detected following an overnight incubation with a 1:250 dilution of anti-
phospho-eIF2α rabbit monoclonal antibody (Cell Signaling Technology, Danvers, MA) 
and a 1 h incubation with a 1:5000 dilution of HRP-conjugated polyclonal anti-rabbit 
antibody (Santa Cruz Biotechnology, Dallas, TX). eIF2α was detected following an 
overnight incubation with a 1:1000 dilution of anti-eIF2α rabbit polyclonal antibody 
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(Cell Signaling Technology, Danvers, MA) and a 1 h incubation with a polyclonal anti-
rabbit HRP secondary antibody. Binding immunoglobulin protein (BiP), also known as 
78 kDa glucose-regulated protein (GRP78), was detected following an overnight 
incubation with a 1:500 dilution of anti-GRP78 rabbit polyclonal antibody (Cell 
Signaling Technology, Danvers, MA) and a 1 h incubation with a polyclonal anti-rabbit 
HRP secondary antibody. Phosphorylated c-Jun-N-terminal kinase (JNK) was detected 
following an overnight incubation with a 1:250 dilution of anti-phospho-JNK rabbit 
monoclonal antibody (Cell Signaling Technology, Danvers, MA) and a 1 h incubation 
with a 1:5000 dilution of HRP-conjugated polyclonal anti-rabbit antibody. JNK was 
detected following an overnight incubation with a 1:1000 dilution of anti-JNK rabbit 
polyclonal antibody (Cell Signaling Technology, Danvers, MA) and a 1 h incubation with 
a polyclonal anti-rabbit HRP secondary antibody. Actin was detected following an 
overnight incubation with a 1:5000 dilution of anti-actin rabbit polyclonal antibody 
(Sigma-Aldrich, St. Louis, MO) and a 1 h incubation with a polyclonal anti-rabbit HRP 
secondary antibody. After subsequent incubations with primary and secondary 
antibodies, membranes were washed 3 times for 5 minutes with TBS-T. Membranes were 
then incubated with BM Chemiluminescence Western Blotting Substrate (POD) (Roche 
Diagnostics, Laval, QC) for 1 minute and exposed on Amersham Hyperfilm (GE 
Healthcare Life Sciences, United Kingdom). Bands corresponding to eEF1A-1 ran beside 
the 50 kDa reference band of the Precision Plus Protein All Blue Standards (Bio-Rad, 
Hercules, CA). Bands corresponding to phospho-eIF2α and eIF2α ran at 38 kDa. Double 
bands corresponding to phospho-JNK and JNK ran as a doublet at 46 and 54 kDa, while 
bands corresponding to GRP78 and actin ran at 78 kDa and 42 kDa, respectively. All 
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bands were quantified by densitometry using Quantity One 1-D Analysis Software (Bio-
Rad, Hercules, CA) and normalized to actin. Phosphorylated protein was normalized to 
total corresponding protein.  
For analyses of protein expression in HepG2 cells following treatments with fatty 
acids in the absence or presence of didemnin B, whole cell lysates were prepared using 
RIPA buffer supplemented with protease and phosphatase inhibitors. GRP78, actin, 
eIF2α and phosphorylated eIF2α protein levels from lysates (20-50 µg) were determined 
by immunoblotting as described above. Bands were quantified by densitometry and 
normalized to actin. Phosphorylated protein was normalized to total corresponding 
protein.  
2.8 [3H] Leucine Incorporation Assays 
For time course experiments using didemnin B, HepG2 cells were plated in 24-
well plates and grown to 70-80% confluency. Cells were treated with 250 µl of palmitate 
supplemented media, or BSA control media, and 80 nM of didemnin B or DMSO as a 
control for 6, 16 and 24 h. Following pre-treatment, 0.25 µCi of L-[4, 5-3H] leucine was 
added to each well. Cells were incubated at 37°C for 60 minutes and then media was 
removed. RIPA buffer was added to each well and incubated on ice for 30 minutes. 
Media was centrifuged at 1000 rpm for 5 minutes at 4°C and the supernatant (secreted 
protein) was precipitated with cold trichloroacetic acid (TCA) for 60 minutes. The RIPA 
buffer cell digest was added to the pellet (non-secreted protein) and precipitated with cold 
TCA for 60 minutes. A sample from the RIPA buffer cell digest was taken, prior to 
precipitation, for total protein quantification using the BCA Protein Assay Kit. Samples 
were centrifuged at 12,000 rpm for 2 minutes at 4°C and washed 3 times in 100% ethanol 
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by resuspension and centrifugation. The pellet was then solubilized in 100 µl 1N NaOH 
and left overnight at room temperature. Samples were prepared using Ecoscint H 
scintillation fluid (National Diagnostics, Atlanta, GA) and counted using a Beckman 
Coulter LS6500 Multipurpose Scintillation Counter (Beckman Coulter, Brea, CA).  
To determine the IC50 of didemnin B and cycloheximide (Sigma-Aldrich, St. 
Louis, MO) for inhibition of protein synthesis, HepG2 cells were plated in 24-well plates 
and grown to 70-80% confluency. Cells were treated with increasing concentrations of 
didemnin B (up to 200 nM) or cycloheximide (up to 500 nM) for 48 h. Following 
treatment, 0.25 µCi of L-[4, 5-3H] leucine was added and the wells were incubated for 60 
minutes. Cells were prepared and counted as described above with the exception of the 
separation of media and supernatant. Media and supernatant were combined and counts 
measured represented the amount of [3H] leucine incorporated into newly synthesized 
protein, and were expressed relative to total protein for each sample. 
2.9 Cell Death 
Cell death and apoptosis were assessed by the Dead Cell Apoptosis Kit 
(Molecular Probes, Eugene, OR) using Alexa Fluor 488 annexin V to stain for apoptosis 
and propidium iodide (PI) to identify membrane permeability. HepG2 cells were pre-
treated for 30 minutes with the previously determined IC50 of didemnin B (80 nM) or 
cycloheximide (50 nM) and then treated with fatty acid media with or without didemnin 
B or cycloheximide for 48 h. Following 48 h incubations, cells were washed in cold 
phosphate-buffered saline (PBS) and harvested by trypsinization. Cells were centrifuged 
and re-suspended in annexin-binding buffer at a density of 1 x 106 cells/ml. A 100 µg/ml 
working solution of PI was prepared by diluting 1 mg/ml PI stock solution in 45 µl of 
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annexin-binding buffer. Cells were stained with 5 µl of Alexa Fluor 488 annexin V and 1 
µl of PI working solution and incubated on ice for 15 minutes in the dark. Samples were 
analysed via flow cytometry, with quantification of 104 cells/sample. Fluorescence 
emission was measured at 530 nm and >575 nm using 488 nm excitation. Dead cells 
were defined as PI positive or annexin V positive and PI positive. Apoptotic cells were 
defined as annexin V positive and PI negative. Live cells were negative for both annexin 
V and PI. 
2.10 Statistical Analyses 
 Statistical analyses were performed using a Student’s t-test or a one-way ANOVA 
followed by Tukey’s post hoc test. Data were displayed as means ± SEM and were 
considered statistically significant at p<0.05. GraphPad Prism version 6.0 software was 
used for statistical analyses and generation of graphs.  
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Chapter 3  
3 Results 
3.1 Didemnin B Treatment Reduces Food Consumption in Obese 
Mice  
eEF1A-1 was previously identified as a mediator of lipotoxic cell death in vitro in 
hepatocytes, and was found to participate in this process downstream of ER stress 
(Stoianov, 2013; Stoianov et al., 2015). Furthermore, we have shown that eEF1A-1 
protein is increased in the livers of ob/ob mice with severe hepatic steatosis (Stoianov, 
2013; Stoianov et al., 2015). Since ER stress is implicated in the pathogenesis of NAFLD 
(Fuchs and Sanyal, 2012), we investigated whether chemical inhibition of eEF1A-1 
activity could improve hepatic lipotoxicity in a mouse model of obesity and metabolic 
syndrome. For this study, five-week old male C57BL/6J (lean control) and leptin 
deficient ob/ob mice were fed AIN-76A diet for 4 weeks. During week 5, mice were 
given i.p. injections of didemnin B (50 µg/kg) or vehicle control on day 1, 4, and 7. Pilot 
studies revealed that ob/ob mice treated with didemnin B consumed less food than ob/ob 
animals treated with vehicle control; therefore, a group of ob/ob mice treated with vehicle 
control were pair-fed to match ob/ob mice treated with didemnin B (Figure 3.1). As 
expected, body weight and epididymal fat weight were significantly increased in all 
ob/ob animals compared to lean control animals (Table 3.1). Neither treatment with 
didemnin B, nor caloric restriction affected body weight or epididymal fat weight over 
the course of the experiment (Table 3.1). 
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Figure 3.1 Didemnin B treatment reduces food consumption in obese mice. 
Five week old C57BL/6J and ob/ob mice were maintained ad libitum or pair fed on AIN-
76A semi-purified diet for 4 weeks. During week 5, mice received 3 i.p. injections of 
either vehicle or didemnin B (50 µg/kg), as indicated, every third day.  Food consumption 
of C57BL/6J (WT), ob/ob, and ob/ob + didemnin B (DB) mice was monitored during 
week 5. A group of ob/ob mice (ob/ob + CR) were pair fed to match the caloric intake of 
ob/ob + DB mice. Data are expressed as means ± SEM, values with different lower case 
letters are significantly different at p<0.05, n=8-12. 
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Table 3.1 Morphometric parameters of metabolic disease in obese mice treated with 
didemnin B.  
Five week old C57BL/6J and ob/ob mice were maintained ad libitum or pair fed (ob/ob + 
Caloric Restriction) on AIN-76A semi-purified diet for 4 weeks. During week 5, mice 
received 3 i.p. injections of either vehicle or didemnin B (50 µg/kg), as indicated, every 
third day. Body weight and epididymal fat weight were determined at sacrifice (day 38). 
Data are expressed as means ± SEM, values with different lower case letters are 
significantly different at p<0.05, n=8-12. 
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3.2 Didemnin B Treatment Reduces Hepatic Lipid Content in 
Obese Mice  
Gross morphology and lipid droplet content of hepatic tissues were assessed by 
H&E and Oil Red O staining, and light microscopy. As expected, Oil Red O stained liver 
tissue sections from ob/ob mice showed increased lipid droplet size compared to sections 
from lean control mice. Interestingly, liver tissues from mice treated with didemnin B 
showed a dramatic reduction in the overall appearance of lipid droplets, while caloric 
restriction resulted in regional reversion of hepatic steatosis (Figure 3.2). We did not 
observe fibrosis in the livers of any of the mice in the four experimental groups. Liver 
weight was decreased 1.3-fold in both didemnin B and calorie restricted animals, 
compared to ob/ob vehicle control mice (Figure 3.3 A). These changes in liver weight 
were associated with significant changes in liver lipid contents which, with the notable 
exception of cholesteryl esters, were similar for didemnin B treated and calorie restricted 
mice. Liver triglyceride levels were decreased 1.5-fold, while liver cholesterol ester 
levels were increased 1.5-fold in didemnin B treated mice compared to ob/ob vehicle 
control mice (Figure 3.3 B, C). No difference in liver free cholesterol levels was observed 
amongst ob/ob vehicle control and treatment groups (Figure 3.3 D).  
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Figure 3.2 Treatment of obese mice with didemnin B decreases appearance of liver 
steatosis.  
Five week old C57BL/6J and ob/ob mice were maintained ad libitum or pair fed on AIN-
76A semi-purified diet for 4 weeks. During week 5, mice received 3 i.p. injections of 
either vehicle or didemnin B (50 µg/kg), as indicated, every third day. Upon sacrifice 
(day 38), liver tissues from C57BL/6J (WT), ob/ob, ob/ob + didemnin B (DB), and ob/ob 
+ calorie restricted (CR) mice were harvested, embedded in OCT, sectioned, and stained 
with either (A) H&E to visualize tissue morphology and inflammatory infiltrates or (B) 
Oil Red O to visualize lipid droplets. Scale bar represents 100 µm. 
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Figure 3.3 Effects of didemnin B treatment on hepatic lipid contents in obese mice.  
Five week old C57BL/6J and ob/ob mice were maintained ad libitum or pair fed on AIN-
76A semi-purified diet for 4 weeks. During week 5, mice received 3 i.p. injections of 
either vehicle or didemnin B (50 µg/kg), as indicated, every third day. Upon sacrifice 
(day 38), liver tissues from C57BL/6J (WT), ob/ob, ob/ob + didemnin B (DB), and ob/ob 
+ calorie restricted (CR) mice were harvested and liver weight (A) was measured. Tissues 
were frozen in liquid nitrogen and triglyceride (TG) (B), cholesterol ester (CE) (C), and 
free cholesterol (FC) (D) concentrations were measured in Folch extracts using standard 
enzymatic, colorimetric assays. Data are expressed as means ± SEM, values with 
different letters are significantly different at p<0.05, n=8-12. 
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3.3 Didemnin B Treatment Improves Plasma Lipid Profiles in 
Obese Mice  
Severe hepatic steatosis and the progression of NAFLD is associated with 
impaired ability of the liver to export triglyceride-rich lipoproteins (VLDL) (Camus et al., 
1988; Coenen et al., 2007; Li et al., 1997; Wiegman et al., 2003). Consistent with this 
early work, plasma triglycerides were decreased in ob/ob mice compared to lean control 
mice (Figure 3.4 A). However, plasma triglycerides were normalized to lean control 
levels in didemnin B and calorie restricted animals. Plasma free fatty acid levels were 
unchanged between experimental groups (Figure 3.4 B). Interestingly, plasma cholesterol 
levels were normalized in didemnin B treated mice, but not in calorie restricted mice 
(Figure 3.4 C). Consistent with these plasma lipid data, plasma lipoprotein profiles for 
VLDL and LDL were normalized by didemnin B treatment, while caloric restriction only 
improved plasma VLDL (Figure 3.5).  
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Figure 3.4 Treatment of obese mice with didemnin B normalizes plasma lipids. 
Five week old C57BL/6J and ob/ob mice were maintained ad libitum or pair fed on AIN-
76A semi-purified diet for 4 weeks. During week 5, mice received 3 i.p. injections of 
either vehicle or didemnin B (50 µg/kg), as indicated, every third day. Plasma 
triglyceride (A), free fatty acids (FFA) (B) and cholesterol (C) were measured in 
C57BL/6J (WT), ob/ob, ob/ob + didemnin B (DB), and ob/ob + calorie restricted (CR) 
mice using standard enzymatic, colorimetric assays. Data are expressed as means ± SEM, 
values with different letters are significantly different at p<0.05, n=8-12.  
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Figure 3.5 Treatment of obese mice with didemnin B normalizes plasma lipoprotein 
profiles.  
Five week old C57BL/6J and ob/ob mice were maintained ad libitum or pair fed on AIN-
76A semi-purified diet for 4 weeks. During week 5, mice received 3 i.p. injections of 
either vehicle or didemnin B (50 µg/kg), as indicated, every third day. Very low density 
lipoprotein (VLDL), low density lipoprotein (LDL) and high density lipoprotein (HDL) 
triglyceride (A) and cholesterol (B) concentrations were measured in eluted fractions of 
plasma from C57BL/6J (WT), ob/ob, ob/ob + didemnin B (DB), and ob/ob + calorie 
restricted (CR) mice, n=4 mice/group.  
 
 
 
 
57 
 
 
 
 
 
 
58 
 
3.4 Didemnin B Treatment Improves Markers of Hepatic 
Lipotoxicity in Obese Mice  
Hepatic lipotoxicity in mouse models of NAFLD is associated with increased 
circulating levels of the liver enzymes ALT and AST, which escape to the circulation 
from damaged hepatocytes (Tsutsumi et al., 2011). Plasma ALT levels in didemnin B 
treated mice and calorie restricted mice were decreased 2.4 and 1.9-fold, respectively, 
compared to ob/ob vehicle control mice. Similarly, plasma AST levels were decreased 
2.3 and 2.0-fold in didemnin B treated and calorie restricted animals, respectively, 
compared to ob/ob vehicle control mice (Figure 3.6). These data suggest that didemnin B 
can improve NAFLD-associated liver damage, but that this effect may be mostly due to 
reduced food intake in these mice.  
ER stress is known to be associated with the progression of NAFLD in mice 
(Zhou and Liu, 2014). Thus, markers of the UPR and ER stress response were assessed in 
all experimental groups. No statistically significant differences in hepatic eEF1A-1 and 
phosphorylated eIF2α protein expression were observed between groups (Figure 3.7, 
Figure 3.8). However, there were trends for increased eEF1A-1 protein expression and 
eIF2α phosphorylation in ob/ob mice compared to lean control mice. Moreover, 
didemnin B treatment and caloric restriction appeared to decrease eEF1A-1 expression 
and eIF2α phosphorylation. Liver GRP78 and phosphorylated JNK expression were 
decreased 2.1 and 1.6-fold respectively, in didemnin B treated mice compared to ob/ob 
vehicle control mice (Figure 3.9, Figure 3.10). Taken together, these data suggest that 
although didemnin B treatment did not inhibit the initiation of ER stress and induction of 
the UPR as indicated by the phosphorylation of eIF2α (an early marker of ER stress), it 
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did contribute to a reduction in the later phases of the ER stress response as indicated by 
decreased upregulation of GRP78 and decreased JNK phosphorylation. 
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Figure 3.6 Effects of didemnin B treatment on plasma ALT and AST levels in obese 
mice. 
Five week old C57BL/6J and ob/ob mice were maintained ad libitum or pair fed on AIN-
76A semi-purified diet for 4 weeks. During week 5, mice received 3 i.p. injections of 
either vehicle or didemnin B (50 µg/kg), as indicated, every third day. Plasma ALT and 
AST were measured in C57BL/6J (WT), ob/ob, ob/ob + didemnin B (DB), and ob/ob + 
calorie restricted (CR) mice using enzymatic rate assays. Data are expressed as means ± 
SEM, values with different letters are significantly different at p<0.05, n=8-12. Capital 
letters are compared to each other while lower case letters are compared to other lower 
case letters.  
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Figure 3.7 Hepatic eEF1A-1 protein is unchanged in obese mice treated with 
didemnin B.  
Five week old C57BL/6J and ob/ob mice were maintained ad libitum or pair fed on AIN-
76A semi-purified diet for 4 weeks. During week 5, mice received 3 i.p. injections of 
either vehicle or didemnin B (50 µg/kg), as indicated, every third day. Upon sacrifice 
(day 38), liver tissues from C57BL/6J (WT), ob/ob, ob/ob + didemnin B (DB), and ob/ob 
+ calorie restricted (CR) mice were harvested and eEF1A-1 protein (50 kDa) was 
detected in whole tissue homogenates. eEF1A-1 protein was detected by immunoblotting 
and quantified by densitometry. Data are expressed relative to actin. Representative blots 
are shown. Data are expressed as means ± SEM, n=8-12. 
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Figure 3.8 Phosphorylation of hepatic eIF2α protein remains unchanged in obese 
mice treated with didemnin B.  
Five week old C57BL/6J and ob/ob mice were maintained ad libitum or pair fed on AIN-
76A semi-purified diet for 4 weeks. During week 5, mice received 3 i.p. injections of 
either vehicle or didemnin B (50 µg/kg), as indicated, every third day. Upon sacrifice 
(day 38), liver tissues from C57BL/6J (WT), ob/ob, ob/ob + didemnin B (DB), and ob/ob 
+ calorie restricted (CR) mice were harvested and phosphorylated eIF2α (P-eIF2α) and 
eIF2α protein (38 kDa) were detected in whole tissue homogenates. P-eIF2α and eIF2α 
protein were detected by immunoblotting and quantified by densitometry. Data are 
expressed relative to total corresponding protein. Representative blots are shown. Data 
are expressed as means ± SEM, n=8-12. 
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Figure 3.9 Hepatic GRP78 protein is decreased in obese mice treated with didemnin 
B.  
Five week old C57BL/6J and ob/ob mice were maintained ad libitum or pair fed on AIN-
76A semi-purified diet for 4 weeks. During week 5, mice received 3 i.p. injections of 
either vehicle or didemnin B (50 µg/kg), as indicated, every third day. Upon sacrifice 
(day 38), liver tissues from C57BL/6J (WT), ob/ob, ob/ob + didemnin B (DB), and ob/ob 
+ calorie restricted (CR) mice were harvested and GRP78 protein (78 kDa) was detected 
in whole tissue homogenates. GRP78 protein was detected by immunoblotting and 
quantified by densitometry. Data are expressed relative to actin. Representative blots are 
shown. Data are expressed as means ± SEM, values with different letters are significantly 
different at p<0.05, n=8-12.  
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Figure 3.10 Phosphorylation of hepatic JNK protein is decreased in obese mice 
treated with didemnin B.  
Five week old C57BL/6J and ob/ob mice were maintained ad libitum or pair fed on AIN-
76A semi-purified diet for 4 weeks. During week 5, mice received 3 i.p. injections of 
either vehicle or didemnin B (50 µg/kg), as indicated, every third day. Upon sacrifice 
(day 38), liver tissues from C57BL/6J (WT), ob/ob, ob/ob + didemnin B (DB), and ob/ob 
+ calorie restricted (CR) mice were harvested and phosphorylated JNK (P-JNK) and JNK 
protein (doublet at 46 and 54 kDa) were detected in whole tissue homogenates. P-JNK 
and JNK protein were detected by immunoblotting and quantified by densitometry. Data 
are expressed relative to total corresponding protein. Representative blots are shown. 
Data are expressed as means ± SEM, values with different letters are significantly 
different at p<0.05, n=8-12. 
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3.5 Didemnin B Treatment Improves Glucose Homeostasis in 
Obese Mice through Decreased Food Intake  
Hepatic lipotoxicity is thought to contribute to insulin resistance and disrupted 
glucose homeostasis during NAFLD (Tessari et al., 2009). Therefore, parameters of 
glucose homeostasis were measured in all experimental groups. Fasting blood glucose 
levels at the time of sacrifice were decreased 1.7 and 1.6-fold in didemnin B and calorie 
restricted animals respectively, compared to ob/ob vehicle control mice (Figure 3.11). 
Oral glucose tolerance was improved in both didemnin B and calorie restricted mice 
(Figure 3.12). Plasma insulin levels were decreased 2.2 and 2.1-fold in didemnin B and 
calorie restricted animals respectively, compared to ob/ob vehicle control mice (Figure 
3.13). No statistically significant differences in insulin tolerance were observed between 
groups (Figure 3.14). These data suggest that improvements in glucose homeostasis 
observed in mice treated with didemnin B can be completely explained by their decreased 
food consumption.  
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Figure 3.11 Effects of didemnin B treatment on fasting blood glucose in obese mice.  
Five week old C57BL/6J and ob/ob mice were maintained ad libitum or pair fed on AIN-
76A semi-purified diet for 4 weeks. During week 5, mice received 3 i.p. injections of 
either vehicle or didemnin B (50 µg/kg), as indicated, every third day. Prior to sacrifice, 
animals were fasted for 6 hours and blood glucose levels were measured in C57BL/6J 
(WT), ob/ob, ob/ob + didemnin B (DB), and ob/ob + calorie restricted (CR) mice using 
an Ascenia Contour glucometer. Data are expressed as means ± SEM, values with 
different letters are significantly different at p<0.05, n=8-12. 
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Figure 3.12 Effects of didemnin B treatment on glucose tolerance in obese mice.  
Five week old C57BL/6J and ob/ob mice were maintained ad libitum or pair fed on AIN-
76A semi-purified diet for 4 weeks. During week 5, mice received 3 i.p. injections of 
either vehicle or didemnin B (50 µg/kg), as indicated, every third day.  Prior to sacrifice, 
glucose tolerance (A) was measured in C57BL/6J (WT), ob/ob, ob/ob + didemnin B 
(DB), and ob/ob + calorie restricted (CR) mice following a 6 h fast and oral gavage of 1 g 
of glucose/kg of body weight. Areas under the curve (AUC) were calculated from data in 
A (B). Data are expressed as means ± SEM, values with different letters are significantly 
different at p<0.05, n=8-12.  
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Figure 3.13 Effects of didemnin B treatment on plasma insulin levels in obese mice.  
Five week old C57BL/6J and ob/ob mice were maintained ad libitum or pair fed on AIN-
76A semi-purified diet for 4 weeks. During week 5, mice received 3 i.p. injections of 
either vehicle or didemnin B (50 µg/kg), as indicated, every third day. Prior to sacrifice, 
animals were fasted for 6 hours and plasma insulin levels were measured in C57BL/6J 
(WT), ob/ob, ob/ob + didemnin B (DB), and ob/ob + calorie restricted (CR) mice using 
ultrasensitive mouse-specific ELISA. Data are expressed as means ± SEM, values with 
different letters are significantly different at p<0.05, n=8-12. 
 
 
 
 
 
 
 
 
 
 
76 
 
 
 
 
 
 
 
 
 
 
 
 
 
77 
 
 
 
 
Figure 3.14 Effects of didemnin B treatment on insulin tolerance in obese mice.  
Five week old C57BL/6J and ob/ob mice were maintained ad libitum or pair fed on AIN-
76A semi-purified diet for 4 weeks. During week 5, mice received 3 i.p. injections of 
either vehicle or didemnin B (50 µg/kg), as indicated, every third day. Prior to sacrifice, 
insulin tolerance (A) was measured in C57BL/6J (WT), ob/ob, ob/ob + didemnin B (DB), 
and ob/ob + calorie restricted (CR) mice following a 6 h fast and i.p. injection of 0.6 IU 
of insulin/kg of body weight. Areas under the curve (AUC) were calculated from data in 
A (B). Data are expressed as means ± SEM, values with different letters are significantly 
different at p<0.05, n=8-12.  
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Together, these studies in mice show that didemnin B treatment modestly 
decreases food intake without overt evidence of illness, and improves parameters 
associated with hepatic lipotoxicity. Liver triglycerides, plasma cholesterol, plasma ALT 
and AST, protein markers of ER stress, fasting blood glucose, and plasma insulin were 
decreased.  Of these observations, only decreased plasma liver enzymes and improved 
glucose homeostasis could be completely attributed to reduced food intake. 
3.6 Didemnin B Decreases Palmitate-Induced ER Stress and Cell 
Death in Cultured Hepatocytes by Inhibiting eEF1A-1 
Protein Synthetic Activity   
Having determined the effect of didemnin B on hepatic lipotoxicity in genetically 
obese mice, we set out to further characterize the mechanism for inhibition of palmitate-
induced cell death by didemnin B in an in vitro model. In this study we used HepG2 
human hepatoma cells because, like human and rodent liver, and unlike other hepatocyte 
cell lines, they exclusively express the eEF1A-1 isoform of eEF1A (Grassi et al., 2007). 
First, the IC50 values for protein synthesis for didemnin B and cycloheximide were 
determined by incorporation of [3H] leucine into newly synthesized proteins (Figure 
3.15A).  Cycloheximide was used as a control in some subsequent experiments because it 
inhibits protein synthesis through a mechanism completely independent of eEF1A-1 
(Schneider-Poetsch et al., 2010). The IC50 of didemnin B was determined to be 80 nM 
whereas the IC50 of cycloheximide was determined to be 50 nM. Cells were then treated 
with 1.0 mM palmitate, with or without 50 nM cycloheximide or 80 nM of didemnin B, 
for 48 h followed by assessment of cell death by flow cytometry. Treatment of HepG2 
cells with palmitate in the presence of didemnin B decreased palmitate induced cell 
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death; however, treatment with cycloheximide had no effect (Figure 3.15 B), suggesting 
that protection from palmitate induced cell death was specific to eEF1A-1 inhibition.  
To determine whether didemnin B limits the burden of protein synthesis during 
fatty acid overload, thereby potentially alleviating ER stress, incorporation of [3H] 
leucine into cellular protein was measured with and without the addition of didemnin B 
over a time course of exposure to growth medium supplemented with 1.0 mM palmitate. 
At the end of each time point, radiolabel was added for 1 h, followed by precipitation of 
total cellular proteins with TCA. Consistent with the onset of ER stress, palmitate 
significantly decreased protein synthesis at 6 h. However, protein synthetic activity 
recovered to approximately 75% of control levels by 24 h (Figure 3.16). This was not the 
case for cells treated with didemnin B, which exhibited sustained suppression of protein 
synthesis up to 24 h. Consistent with these protein synthesis data, the onset of ER stress 
in response to palmitate (as assessed by eIF2α phosphorylation) was not affected by 
incubation with didemnin B (Figure 3.17). However, didemnin B did prevent 
upregulation of GRP78 protein in response to palmitate (Figure 3.18), suggesting that 
inhibition of eEF1A-1 diminishes the later stages of ER stress during which protein 
production is re-established, further increasing the burden on this organelle (Krokowski 
et al., 2013; Stoianov, 2013; Stoianov et al., 2015). This could prevent subsequent cell 
death, as observed with didemnin B in Figure 3.15 B, by allowing the ER to recover and 
restore homeostasis.  
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Figure 3.15 Decreased palmitate induced cell death is selective for inhibition of 
eEF1A-1 dependent protein synthesis.  
HepG2 cells were treated for 48 h with increasing concentrations of didemnin B (DB) 
(eEF1A-1 elongation function inhibitor), cycloheximide (CHX) (inhibitor of protein 
synthesis independent of eEF1A-1 activity), or DMSO as a control, followed by 
assessment of total protein synthesis by [3H] leucine incorporation (A). The IC50 for 
protein synthesis with didemnin B was 80 nM, the IC50 for protein synthesis with 
cycloheximide was 50 nM. HepG2 cells were incubated for 48 h with growth media 
containing BSA or 1.0 mM palmitate (PA) conjugated to BSA at a molar ratio of 2:1, in 
the presence or absence of 80 nM didemnin B (IC50) or 50 nM cycloheximide (IC50). 
Cells were harvested and stained with annexin V (Ann V) and PI and the proportions of 
live cells (Ann V- PI-), apoptotic cells (Ann V+ PI-) and dead cells (Ann V+ PI+) were 
determined by flow cytometry (B). For A, data are expressed as percentages of control 
(vehicle) ± SEM, n=3. For B, data are expressed as means ± SEM, values with different 
letters are significantly different at p<0.05, n=4. 
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Figure 3.16 Inhibition of eEF1A-1 elongation function suppresses protein synthesis 
during saturated fatty acid overload.  
HepG2 cells were incubated for 6, 16 and 24 h with growth media containing BSA or 1.0 
mM palmitate (PA) conjugated to BSA at a molar ratio of 2:1, in the presence or absence 
of 80 nM didemnin B (DB) or DMSO as a control, followed by assessment of total 
protein synthesis by [3H] leucine incorporation. Data are expressed as means ± SEM, 
values with different letters are significantly different at p<0.05 within time points, n=5. 
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Figure 3.17 Didemnin B does not prevent phosphorylation of eIF2α protein during 
saturated fatty acid overload in HepG2 cells.  
HepG2 cells were incubated for 6 h with growth media containing BSA or 1.0 mM 
palmitate (PA) conjugated to BSA at a molar ratio of 2:1, in the presence or absence of 
80 nM didemnin B (DB) or DMSO as a control. Phosphorylated (P-eIF2α) and total 
eIF2α protein (38 kDa) were detected in whole cell lysates by immunoblotting. Bands 
were quantified by densitometry and normalized to total eIF2α. Representative blots are 
shown. Data are expressed as means ± SEM, *p<0.05, n=4. 
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Figure 3.18 Didemnin B prevents GRP78 protein upregulation during saturated 
fatty acid overload in HepG2 cells.  
HepG2 cells were incubated for 6 h with growth media containing BSA or 1.0 mM 
palmitate (PA) conjugated to BSA at a molar ratio of 2:1, in the presence or absence of 
80 nM didemnin B (DB) or DMSO as a control. GRP78 protein (78 kDa) was detected in 
whole cell lysates by immunoblotting. Bands were quantified by densitometry and 
normalized to actin. Representative blots are shown. Black vertical lines on the blots 
indicate that lanes from the same blot were re-ordered for presentation purposes. Data are 
expressed as means ± SEM, *p<0.05, n=4. 
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Chapter 4  
4 Discussion 
4.1 Summary of Results  
The prevalence of NAFLD has increased dramatically over the past several 
decades with as much as 30% of the population of the western world now affected 
(Schwenger and Allard, 2014; Tuyama and Chang, 2012). Remarkably, this prevalence 
rises to 75-80% in obese patients, making NAFLD one of the most common liver 
diseases in developed countries (Tuyama and Chang, 2012). Despite the pervasiveness of 
NAFLD, little is known about the pathogenesis of this disease. Based on previous 
findings identifying eEF1A-1 as a mediator of lipotoxicity in CHO cells, cardiomyocytes, 
and hepatocytes, a role for this protein in lipotoxic disease in vivo, in a mouse model of 
obesity and NAFLD, was proposed (Borradaile et al., 2006a; Stoianov, 2013; Stoianov et 
al., 2015). For this thesis it was hypothesized that inhibition of eEF1A-1 peptide 
elongation activity would decrease hepatocyte ER stress and lipotoxicity in the livers of 
obese mice. A series of studies revealed several key findings: 1) Treatment of obese mice 
with didemnin B, a specific chemical inhibitor of eEF1A-1 peptide elongation function, 
modestly decreased food intake without overt evidence of illness; 2) Didemnin B 
treatment reduced liver triglycerides, protein markers of ER stress, plasma ALT and 
AST, fasting blood glucose, plasma insulin, and plasma cholesterol. Of these 
observations, only decreased plasma liver enzymes and improved glucose homeostasis 
could be completely attributed to reduced food intake. 3) Specific inhibition of the 
elongation function of eEF1A-1 with didemnin B in hepatocytes reduced palmitate-
induced ER stress and cell death. Taken together, these findings support the conclusion 
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that inhibition of eEF1A-1 activity with didemnin B improved characteristics of hepatic 
ER stress and lipotoxicity in obese mice with NAFLD.  
4.2 Didemnin B Treatment Reduces Food Consumption in Obese 
Mice 
Our data from a genetic mouse model of obesity indicate that treatment with 
didemnin B leads to a reduction in food consumption with no overt evidence of illness or 
toxicity, and no decreases in body weight or fat pad mass over the treatment period (10 
days). Didemnin B is a cyclic depsipeptide (Marco et al., 2004), and due to its size it is 
unable to cross the blood brain barrier. Therefore, we hypothesize that the observed 
reduction in food consumption is most likely not related to a neural signal, but possibly a 
gut signal. Furthermore, the mouse model we used is leptin deficient making it unlikely 
that the mechanism of reduced food consumption involved the leptin signaling pathway. 
Instead, it is possible that inhibition of an orexigenic peptide, such as ghrelin, is involved. 
Concentrations of didemnin B following i.p. administration in mice are greatest in the 
liver, digestive tract, and pancreas (Beasley et al., 2005). The stomach is the major source 
of circulating ghrelin, however ghrelin is also released by the intestine and pancreas 
(Wierup et al., 2014). Therefore, it is possible that in our study didemnin B, by inhibiting 
protein synthesis in the digestive tract and pancreas, inhibited ghrelin production 
resulting in appetite suppression and decreased food consumption in ob/ob mice. Further 
studies are required to test this possibility.  
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4.3 Didemnin B Treatment Reduces Hepatic Lipid Contents and 
Improves Plasma Lipid Profiles in Obese Mice 
Treatment of obese mice with didemnin B decreased liver triglyceride content 
while increasing plasma VLDL and triglycerides suggesting that intervention with 
didemnin B was able to normalize hepatic steatosis and triglyceride-rich lipoprotein 
export. The decrease in plasma triglyceride and VLDL levels, and increase in liver 
triglyceride content we observed in ob/ob control mice were consistent with findings in 
other studies. Ob/ob mice are well characterized, and are known to have increased ER 
stress in the liver (Ai et al., 2012) that impairs the ability of the hepatocyte to produce 
and secrete VLDL (Camus et al., 1988; Coenen et al., 2007; Li et al., 1997; Wiegman et 
al., 2003). This results in decreased export of triglyceride in VLDL, decreased circulating 
levels of VLDL, and increased hepatic triglyceride accumulation that contributes to 
steatosis. The effects of didemnin B treatment on hepatic lipid contents and on plasma 
triglyceride and VLDL concentrations can be explained by decreased food intake. 
Decreased delivery of dietary lipids to the liver can decrease steatosis and associated 
hepatocyte ER stress, allowing the liver to restore export of triglyceride in VLDL. This 
concept is supported by our observations of increased plasma triglyceride and VLDL 
triglycerides, to levels observed in lean control mice, in both didemnin B treated and 
calorie restricted ob/ob mice. Unlike the changes observed in liver and plasma 
triglycerides, increased liver cholesteryl ester content and decreased plasma cholesterol 
and LDL were unique to mice treated with didemnin B. An increase in LDL receptor 
(LDLR) expression and subsequent LDL clearance by the liver could explain the 
increased hepatic cholesteryl ester content, decreased plasma cholesterol levels and levels 
of cholesterol associated with LDL observed in these mice. Further experiments would be 
92 
 
required to confirm that LDLR expression and LDL clearance were increased by 
didemnin B treatment. However, from the data in this thesis, it can be concluded that 
didemnin B treatment may play a role in normalizing hepatic triglyceride content and 
plasma triglyceride levels, as well as normalizing plasma lipoprotein profiles in ob/ob 
animals by mitigating eEF1A-1 mediated ER stress.  
4.4 Didemnin B Treatment Improves Markers of Hepatic 
Lipotoxicity and ER Stress in Obese Mice 
Plasma liver enzymes and some protein markers of ER stress were normalized in 
obese mice treated with didemnin B. The reduction in plasma ALT and AST levels 
observed could be explained by decreased food intake, and subsequent reductions in 
lipotoxic cell stress and hepatocyte injury (Tsutsumi et al., 2011). Moreover, these results 
indicate that treatment with didemnin B at this low dose (50 µg/kg) does not cause 
hepatic toxicity. Although there was no difference in eIF2α phosphorylation in the livers 
of didemnin B treated ob/ob mice, hepatic GRP78 protein content and phosphorylation of 
JNK were decreased in didemnin B treated animals. The decrease in GRP78 protein 
content and JNK phosphorylation, accompanied by a lack of change in eIF2α 
phosphorylation, suggests that didemnin B does not prevent the initiation of the UPR but 
does reduce ER stress by inhibiting downstream UPR and ER stress markers (Ibrahim 
and Gores, 2012; Zhou and Liu, 2014). Previous studies have implicated eEF1A-1 as a 
mediator of hepatic ER stress in vitro through its contribution to protein synthesis in the 
setting of excess ER anabolic burden (Stoianov, 2013; Stoianov et al., 2015). These 
previous findings, along with evidence presented in this thesis suggest that inhibition of 
eEF1A-1 with didemnin B mitigates hepatic ER stress and subsequent lipotoxicity during 
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NAFLD. Thus, it is possible that eEF1A-1 may play a role in the progression of this 
chronic liver disease.   
4.5 Improved Glucose Homeostasis in Obese Mice Can Be 
Explained by Decreased Food Intake 
Our data also show that treatment with didemnin B improves glucose 
homeostasis. However, the effects of didemnin B treatment on glucose tolerance and 
insulin sensitivity could be completely explained by decreased food intake. Our findings 
are consistent with previous studies in ob/ob and db/db mice that show caloric restriction 
improves glucose tolerance and insulin sensitivity (Stranahan et al., 2009; Tsutsumi et al., 
2011; van den Hoek et al., 2008). However, i.p. administration of didemnin B is known 
to result in accumulation of this molecule in the pancreas. Therefore, pancreatic tissue 
should be further examined to ensure that decreased plasma insulin observed in didemnin 
B treated mice is due entirely to improved insulin sensitivity, and not the result of 
pancreatic islet damage and/or inhibition of protein synthesis in the pancreas.  
4.6 Inhibition of eEF1A-1 Peptide Elongation Function and 
Cultured Hepatocyte Responses to Palmitate-Induced ER 
Stress and Cell Death  
In HepG2 cells, didemnin B (at its IC50 for protein synthesis) decreased palmitate-
induced upregulation of GRP78, but not the initiation of the UPR as measured by eIF2α 
phosphorylation. Inhibition of eEF1A-1 peptide elongation function with didemnin B 
under basal conditions did not trigger feedback stimulation of eIF2α phosphorylation. 
This is consistent with our in vivo data and with recent studies in yeast strains with 
mutations that interfere specifically with the peptide elongation function of eEF1A-1 
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(Perez and Kinzy, 2014). Didemnin B also prevented the recovery of protein synthesis 
that is known to occur during chronic ER stress and contributes to subsequent cell death 
by increasing the burden on the already overwhelmed ER (Guan et al., 2014). It is likely 
that didemnin B does not prevent the early effects of excess palmitate on ER membrane 
composition (Borradaile et al., 2006b) that result in ER stress and phosphorylation of 
eIF2α. However, as supported by the observed decrease in palmitate-induced 
upregulation of GRP78 and sustained suppression of protein synthesis with didemnin B 
in the presence of palmitate, it is likely that inhibition of eEF1A-1 dependent protein 
synthesis at the ER is protective during lipotoxicity. This concept is further supported by 
studies that suggest alleviating ER stress and the accumulation of unfolded and misfolded 
proteins may be a viable therapeutic strategy for the treatment of NAFLD (Ibrahim et al., 
2011). Interestingly, specific inhibition of eEF1A-1 dependent protein synthesis using 
didemnin B decreased palmitate-induced cell death, while inhibition of protein synthesis 
using cycloheximide had no effect on cell survival. This suggests that protection from 
palmitate-induced cell death may be specific to eEF1A-1 dependent protein synthesis, 
perhaps due to its predominant localization to the ER. Together, the findings of this thesis 
support a role for eEF1A-1 dependent protein synthesis in the promotion of lipotoxicity, 
and suggest that inhibition of this activity with didemnin B reduces ER stress and 
lipotoxic cell death in hepatocytes. 
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Figure 4.1 Working model of the role of eEF1A-1 and didemnin B in the pathways 
involved in hepatocyte lipotoxicity. 
Excess saturated fatty acids, such as palmitate, can overwhelm the ability of a hepatocyte 
to store them as triglycerides (lipid droplets), to catabolise them through β-oxidation in 
the mitochondria, and to export them as triglycerides in lipoproteins. This can result in 
the production of reactive oxygen species (ROS) which can lead to oxidative and ER 
stress. Excess palmitate can also impair the structure and integrity of the ER membrane. 
Oxidative stress and impaired ER structure leads to a release of ER calcium which can 
initiate cell death pathways. Under basal conditions, eEF1A-1 (green circles) is 
predominantly localized to the ER. Fatty acid overload results in the mobilization of 
eEF1A-1 from the ER to the actin (red circles) cytoskeleton. eEF1A-1 may mediate 
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changes in the actin cytoskeleton that are necessary for the progression of cell death 
and/or may promote cell death through its protein synthetic activity at the ER. Didemnin 
B (DB) specifically binds GTP-bound eEF1A-1 (black circles) at the ribosome, and 
inhibits peptidyl-tRNA translocation and peptide elongation. At the ER, this alleviates 
ER stress by preventing any further protein synthetic burden, resulting in protection from 
cell death, possibly including apoptosis, necrosis, and anoikis.  
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4.7 Future Directions and Limitations of Study 
A working model for the roles eEF1A-1 and didemnin B play in the 
hepatocellular response to saturated fatty acid induced stress is summarized in Figure 4.1. 
Based on this model, and our observations in obese mice treated with didemnin B, several 
lines of further experimentation are warranted. However, perhaps the most critical 
experiment required to support the hypothesis outlined in Section 1.6, is to determine 
whether or not didemnin B inhibits total protein synthesis in the liver in vivo. This is a 
challenging experiment to perform in obese mice undergoing chronic ER stress because 
protein synthesis is already suppressed. However, it may be possible to measure plasma 
albumin levels in lean control mice upon treatment with didemnin B to address this 
question. It is important to note that any observed changes in this setting could also be 
attributed to impaired kidney function (Seimiya et al., 2014).  
We have hypothesized that the reduction in food consumption observed in ob/ob 
animals treated with didemnin B may be due to the inhibition of ghrelin production or 
action. To test this hypothesis, we could assess circulating plasma ghrelin levels and 
ghrelin expression in tissues known to produce this hormone, such as the pancreas, 
stomach and intestine (Yada et al., 2008).  
To further confirm the effects of didemnin B on improving clinical characteristics 
of NAFLD, histological sections of hepatic tissue stained with H&E could be graded 
using the NAFLD Activity Score (NAS) scoring system described by Takahashi and 
Fukusato (2014). Using this scoring system, the severity of NAFLD is evaluated based on 
the presence of steatosis, Mallory-Denk bodies, lobular inflammation, and hepatocyte 
ballooning, to accurately identify the disease from mild (benign steatosis) to severe 
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(NASH). Mice on a C57BL/6J background, as is the case for ob/ob mice, do not develop 
fibrosis with NAFLD (Anstee and Goldin, 2006), thus disease grading for this method 
would be limited to pre-fibrotic NAFLD.  
To further support our conclusion that treatment with didemnin B improves 
hepatic lipotoxicity in obese mice with NAFLD, the expression of several genes could be 
examined by real-time quantitative polymerase chain reaction (rtQPCR). Data about 
metabolic gene expression would help to determine if the effects of didemnin B were 
associated with changes in de novo lipogenesis, lipid export, or clearance from the 
circulation and catabolism. Hepatic diglyceride acyltransferase (DGAT), fatty acid 
synthase (FAS), and SREBP-1c expression would provide further insight into the effects 
of didemnin B on liver triglyceride, fatty acid, and cholesterol synthesis, respectively 
(Nakamura et al., 2014). LDLR expression, along with lipoprotein kinetic studies, would 
help to elucidate whether the increased hepatic cholesteryl ester content, decreased 
plasma cholesterol levels and levels of cholesterol associated with LDL we observed in 
didemnin B treated animals were due to upregulation of LDLR and a subsequent increase 
in LDL clearance. Furthermore, hepatic XBP1 expression would provide us with further 
information about the mitigating effects of didemnin B treatment on ER stress (Henkel 
and Green, 2013). 
Didemnin B is known to distribute to the pancreas in rodent models (Beasley et 
al., 2005). Due to the reduction in plasma insulin levels we observed in didemnin B 
treated mice, it is important to confirm whether this is solely a result of improved glucose 
homeostasis or due to impaired insulin production resulting from the inhibition of protein 
synthesis in pancreatic β-cells. To determine if treatment with didemnin B alters islet size 
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and insulin content relative to control and calorie restricted animals, pancreatic serial 
sections will be stained for insulin, and islet areas and insulin-positive islet cells will be 
quantified.  
The chemotherapeutic activity of didemnin B was clinically tested in humans, 
however, these phase II clinical trials failed due to ineffective antitumor activity 
combined with intestinal toxicity (Benvenuto et al., 1992; Marco et al., 2004; Mittelman 
et al., 1999; Shin et al., 1994; Shin et al., 1991). Doses of didemnin B in these trials 
ranged from 3.47 mg/m2 to 9.1 mg/m2 (Shin et al., 1991), which is approximately 0.09 
mg/kg to 0.25 mg/kg. Although a much lower dose (50 µg/kg) was used for the studies in 
this thesis, and no overt evidence of illness or functional systemic toxicity was observed 
in didemnin B treated animals, intestinal sections should be further assessed. Intestinal 
toxicity could be determined by staining serial sections of ileum and jejunum with H&E 
and examining sections for apparent pathology using light microscopy. In addition, 
sections could be stained for markers of enterocyte proliferation such as Ki67, to 
determine if didemnin B treatment results in abnormal cell proliferation (Bacchi and 
Gown, 1993; Yu and Filipe, 1993; Yu et al., 1992)  
 As discussed earlier, the ob/ob mouse model is resistant to NAFLD associated 
fibrosis (Anstee and Goldin, 2006). Therefore, to investigate the role of eEF1A-1 and the 
effect of didemnin B treatment on NASH and fibrosis in vivo, a different mouse model 
would be required. Studies using 129/SVJ mice fed a high fat diet for 6 months indicate 
that these animals develop obesity, hepatic steatosis, insulin resistance, and liver fibrosis 
(Syn et al., 2009). This diet-induced model of NAFLD and fibrosis would be more 
representative of the disease found in the human population and would be useful to 
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conduct further experiments to investigate the role of eEF1A-1 in the end stages of 
NAFLD.  
Finally, the liver is composed of a variety of cells other than hepatocytes, 
including hepatic stellate cells, sinusoidal endothelial cells, and Kupffer cells (Peverill et 
al., 2014). Activated hepatic stellate cells are myofibroblast-like cells that produce 
extracellular matrix and are the principle cell type responsible for hepatic fibrosis 
associated with NASH (Fujii and Kawada, 2012). Our knowledge of lipotoxicity in 
hepatic stellate cells is limited, but it is possible that eEF1A-1 may play a role in the 
progression of fibrosis, especially given its function in protein synthesis under conditions 
of cell stress. Further experiments investigating the effects of reduced eEF1A-1 
expression and activity in primary hepatic stellate cells and in a mouse model of NAFLD 
fibrosis may provide insight into the role(s) that eEF1A-1 plays throughout the entire 
liver during all stages of NAFLD progression.  
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